

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A01N 63/00, A61K 39/00, C07H 17/00, C12N 5/00, 15/00	A1	(11) International Publication Number: WO 95/21528 (43) International Publication Date: 17 August 1995 (17.08.95)
(21) International Application Number: PCT/US95/00454 (22) International Filing Date: 12 January 1995 (12.01.95) (30) Priority Data: 08/195,395 14 February 1994 (14.02.94) US 08/284,391 2 August 1994 (02.08.94) US (71) Applicant: THE GENERAL HOSPITAL CORPORATION [US/US]; 55 Fruit Street, Boston, MA 02114 (US). (72) Inventors: SEED, Brian; Apartment 5J, 9 Hawthorne Place, Boston, MA 02114 (US). BANAPOUR, Babak; 112 Big Bear Court, El Sobrante, CA 94803 (US). ROMEO, Charles; 45 Chester Road, Belmont, MA 02178 (US). KOLANUS, Waldemar; Gosswinstrasse 7, D-81245 Munchen (DE). (74) Agent: CLARK, Paul, T.; Fish & Richardson P.C., 225 Franklin Street, Boston, MA 02110-2804 (US).		(81) Designated States: AU, BR, BY, CA, CN, CZ, FI, HU, JP, KR, MX, NO, NZ, PL, RU, SI, UA. European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i>
(54) Title: TARGETED CYTOLYSIS OF HIV-INFECTED CELLS BY CHIMERIC CD4 RECEPTOR-BEARING CELLS (57) Abstract Disclosed is a method of directing a cellular immune response against an HIV-infected cell in a mammal involving administering to the mammal an effective amount of therapeutic cells which express a membrane-bound, proteinaceous chimeric receptor comprising (a) an extracellular portion which includes a fragment of CD4 which is capable of specifically recognizing and binding the HIV-infected cell but which does not mediate HIV infection and (b) an intracellular portion which is capable of signalling the therapeutic cell to destroy the receptor-bound HIV-infected cell. Also disclosed are cells which express the chimeric receptors and DNA and vectors encoding the chimeric receptors.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

- 1 -

TARGETED CYTOLYSIS OF HIV-INFECTED CELLS BY CHIMERIC
CD4 RECEPTOR-BEARING CELLS

5 Field of the Invention

 This invention was made with Government support under Contract #AI 27849 awarded by the National Institutes of Health. The Government has certain rights in this invention.

10 The invention concerns functional chimeras between CD4 fragments and immune cell receptors which are capable of directing immune cells to lyse HIV-infected cells, but which do not render the immune cells susceptible to HIV infection. The invention therefore provides a novel and
15 effective HIV therapeutic.

Background of the Invention

 T cell recognition of antigen through the T cell receptor is the basis of a range of immunological phenomena. The T cells direct what is called cell-
20 mediated immunity. This involves the destruction by cells of the immune system of foreign tissues or infected cells. A variety of T cells exist, including "helper" and "suppressor" cells, which modulate the immune response, and cytotoxic (or "killer") cells, which can
25 kill abnormal cells directly.

 A T cell that recognizes and binds a unique antigen displayed on the surface of another cell becomes activated; it can then multiply, and if it is a cytotoxic cell, it can kill the bound cell.

30 HIV and Immunopathogenesis

 In 1984 HIV was shown to be the etiologic agent of AIDS. Since that time the definition of AIDS has been revised a number of times with regard to what criteria

- 2 -

should be included in the diagnosis. However, despite the fluctuation in diagnostic parameters, the simple common denominator of AIDS is the infection with HIV and subsequent development of persistent constitutional

5 symptoms and AIDS-defining diseases such as a secondary infections, neoplasms, and neurologic disease.

Harrison's Principles of Internal Medicine, 12th ed., McGraw Hill (1991).

HIV is a human retrovirus of the lentivirus group.

10 The four recognized human retroviruses belong to two distinct groups: the human T lymphotropic (or leukemia) retroviruses, HTLV-1 and HTLV-2, and the human immunodeficiency viruses, HIV-1 and HIV-2. The former are transforming viruses whereas the latter are
15 cytopathic viruses.

HIV-1 has been identified as the most common cause of AIDS throughout the world. Sequence homology between HIV-2 and HIV-1 is about 40% with HIV-2 being more closely related to some members of a group of simian
20 immunodeficiency viruses (SIV). See Curran, J. et al., Science, 329:1357-1359 (1985); Weiss, R. et al., Nature, 324:572-575 (1986).

HIV has the usual retroviral genes (env, gag, and pol) as well as six extra genes involved in the
25 replication and other biologic activities of the virus. As stated previously, the common denominator of AIDS is a profound immunosuppression, predominantly of cell-mediated immunity. This immune suppression leads to a variety of opportunistic diseases, particularly certain
30 infections and neoplasms.

The main cause of the immune defect in AIDS has been identified as a quantitative and qualitative deficiency in the subset of thymus-derived (T) lymphocytes, the T4 population. This subset of cells is
35 defined phenotypically by the presence of the CD4 surface

- 3 -

molecule, which has been demonstrated to be the cellular receptor for HIV. Dalglish et al., Nature 312:763 (1984). Although the T4 cell is the major cell type infected with HIV, essentially any human cell that
5 expresses the CD4 molecule on its surface is capable of binding to and being infected with HIV.

Traditionally, CD4⁺ T cells have been assigned the role of helper/inducer, indicating their function in providing an activating signal to B cells, or inducing T
10 lymphocytes bearing the reciprocal CD8 marker to become cytotoxic/suppressor cells. Reinherz and Schlossman, Cell 19:821-827 (1980); Goldstein et al., Immunol. Rev. 68:5-42 (1982).

HIV binds specifically and with high affinity, via
15 a stretch of amino acids in the viral envelope (gp120), to a portion of the V1 region of the CD4 molecule located near its N-terminus. Following binding, the virus fuses with the target cell membrane and is internalized. Once internalized it uses the enzyme reverse transcriptase to
20 transcribe its genomic RNA to DNA, which is integrated into the cellular DNA where it exists for the life of the cell as a "provirus."

The provirus may remain latent or be activated to transcribe mRNA and genomic RNA, leading to protein
25 synthesis, assembly, new virion formation, and budding of virus from the cell surface. Although the precise mechanism by which the virus induces cell death has not been established, it is believed that the major mechanism is massive viral budding from the cell surface, leading
30 to disruption of the plasma membrane and resulting osmotic disequilibrium.

During the course of the infection, the host organism develops antibodies against viral proteins, including the major envelope glycoproteins gp120 and
35 gp41. Despite this humoral immunity, the disease

- 4 -

progresses, resulting in a lethal immunosuppression characterized by multiple opportunistic infections, parasitemia, dementia, and death. The failure of the host anti-viral antibodies to arrest the progression of the disease represents one of the most vexing and alarming aspects of the infection, and augurs poorly for vaccination efforts based upon conventional approaches.

Two factors may play a role in the efficacy of the humoral response to immunodeficiency viruses. First, like other RNA viruses (and like retroviruses in particular), the immunodeficiency viruses show a high mutation rate in response to host immune surveillance. Second, the envelope glycoproteins themselves are heavily glycosylated molecules presenting few epitopes suitable for high affinity antibody binding. The poorly antigenic target which the viral envelope presents allows the host little opportunity for restricting viral infection by specific antibody production.

Cells infected by the HIV virus express the gp120 glycoprotein on their surface. Gp120 mediates fusion events among CD4⁺ cells via a reaction similar to that by which the virus enters the uninfected cells, leading to the formation of short-lived multinucleated giant cells. Syncytium formation is dependent on a direct interaction of the gp120 envelope glycoprotein with the CD4 protein. Dalglish et al., supra; Klatzman, D. et al., Nature 312:763 (1984); McDougal, J.S. et al., Science 231:382 (1986); Sodroski, J. et al., Nature 322:470 (1986); Lifson, J.D. et al., Nature 323:725 (1986); Sodroski, J. et al., Nature 321:412 (1986).

Evidence that the CD4-gp120 binding is responsible for viral infection of cells bearing the CD4 antigen includes the finding that a specific complex is formed between gp120 and CD4. McDougal et al., supra. Other investigators have shown that the cell lines, which were

- 5 -

noninfective for HIV, were converted to infectable cell lines following transfection and expression of the human CD4 cDNA gene. Maddon et al., Cell 46:333-348 (1986).

Therapeutic programs based on soluble CD4 as a
5 passive agent to interfere with viral adsorption and syncytium-mediated cellular transmission have been proposed and successfully demonstrated in vitro by a number of groups (Deen et al., Nature 331:82-84 (1988); Fisher et al., Nature 331:76-78 (1988); Hussey et al.,
10 Nature 331:78-81 (1988); Smith et al., Science 238:1704-1707 (1987); Trauneker et al., Nature 331:84-86 (1988)); and CD4 immunoglobulin fusion proteins with extended halflives and modest biological activity have subsequently been developed (Capon et al., Nature
15 337:525-531 (1989); Trauneker et al. Nature 339, 68-70 (1989); Byrn et al., Nature 344:667-670 (1990); Zettlmeissl et al., DNA Cell Biol. 9:347-353 (1990)). Although CD4 immunotoxin conjugates or fusion proteins show potent cytotoxicity for infected cells in vitro
20 (Chaudhary et al., Nature 335:369-372 (1988); Till et al., Science 242:1166-1168 (1988)), the latency of the immunodeficiency syndrome makes it unlikely that any single-treatment therapy will be effective in eliminating viral burden, and the antigenicity of foreign fusion
25 proteins is likely to limit their acceptability in treatments requiring repetitive dosing. Trials with monkeys affected with SIV have shown that soluble CD4, if administered to animals without marked CD4 cytopenia, can reduce SIV titer and improve in vitro measures of myeloid
30 potential (Watanabe et al., Nature 337:267-270 (1989)). However a prompt viral reemergence was observed after treatment was discontinued, suggesting that lifelong administration might be necessary to prevent progressive immune system debilitation.

- 6 -

T Cell and Fc Receptors

Cell surface expression of the most abundant form of the T cell antigen receptor (TCR) requires the coexpression of at least 6 distinct polypeptide chains (Weiss et al., J. Exp. Med. 160:1284-1299 (1984); Orloffhashi et al., Nature 316:606-609 (1985); Berkhout et al., J. Biol. Chem. 263:8528-8536 (1988); Sussman et al., Cell 52:85-95 (1988)), the α/β antigen binding chains, the three polypeptides of the CD3 complex, and ζ . If any of the chains are absent, stable expression of the remaining members of the complex does not ensue. ζ is the limiting polypeptide for surface expression of the complete complex (Sussman et al., Cell 52:85-95 (1988)) and is thought to mediate at least a fraction of the cellular activation programs triggered by receptor recognition of ligand (Weissman et al., EMBO J. 8:3651-3656 (1989); Frank et al., Science 249:174-177 (1990)). A 32kDa type I integral membrane homodimer, ζ (zeta) has a 9 residue extracellular domain with no sites for N-linked glycan addition, and a 112 residue (mouse) or 113 residue (human) intracellular domain (Weissman et al., Science 238:1018-1020 (1988); Weissman et al., Proc. Natl. Acad. Sci. USA 85:9709-9713 (1988)). An isoform of ζ called η (eta) (Baniyash et al., J. Biol. Chem. 263:9874-9878 (1988); Orloff et al., J. Biol. Chem. 264:14812-14817 (1989)), which arises from an alternate mRNA splicing pathway (Jin et al., Proc. Natl. Acad. Sci. USA 87:3319-3233 (1990)), is present in reduced amounts in cells expressing the antigen receptor. ζ - η heterodimers are thought to mediate the formation of inositol phosphates, as well as the receptor-initiated programmed cell death called apoptosis (Merćep et al., Science 242:571-574 (1988); Merćep et al., Science 246:1162-1165 (1989)).

- 7 -

Like ζ and η , the Fc receptor-associated γ chain is expressed in cell surface complexes with additional polypeptides, some of which mediate ligand recognition, and others of which have undefined function. γ (gamma) bears a homodimeric structure and overall organization very similar to that of ζ and is a component of both the mast cell/basophil high affinity IgE receptor, Fc ϵ RI, which consists of at least three distinct polypeptide chains (Blank et al., Nature 337:187-189 (1989); Ra et al., Nature 241:752-754 (1989)), and one of the low affinity receptors for IgG, represented in mice by Fc γ RII α (Ra et al., J. Biol. Chem. 264:15323-15327 (1989)), and in humans by the CD16 subtype expression by macrophages and natural killer cells, CD16_{TM} (CD16 transmembrane) (Lanier et al., Nature 342:803-805 (1989); Anderson et al., Proc. Natl. Acad. Sci. USA 87:2274-2278 (1990)) and with a polypeptide of unidentified function (Anderson et al., Proc. Natl. Acad. Sci. USA 87:2274-2278 (1990)). Recently it has been reported that γ is expressed by a mouse T cell line, CTL, in which it forms homodimers as well as γ - ζ and γ - η heterodimers (Orloff et al., Nature 347:189-191 (1990)).

The Fc receptors mediate phagocytosis of immune complexes, transcytosis, and antibody dependent cellular cytotoxicity (ADCC) (Ravetch and Kinet, Annu. Rev. Immunol. 9:457-492 (1991); Unkeless et al., Annu. Rev. Immunol. 6:251-281 (1988); and Mellman, Curr. Opin. Immunol. 1:16-25 (1988)). Recently it has been shown that one of the murine low affinity Fc receptor isoforms, Fc γ RIIIB1, mediates internalization of Ig-coated targets into clathrin coated pits, and that another low affinity receptor, Fc γ RIIIA mediates ADCC through its association with one or more members of a small family of 'trigger molecules' (Miettinen et al., Cell 58:317-327 (1989); and Hunziker and Mellman, J. Cell Biol. 109:3291-3302

- 8 -

(1989)). These trigger molecules, T cell receptor (TCR) ζ chain, TCR η chain, and Fc receptor γ chain interact with ligand recognition domains of different immune system receptors and can autonomously initiate cellular effector programs, including cytolysis, following aggregation (Samelson et al., Cell 43:223-231 (1985); Weissman et al., Science 239:1018-1020 (1988); Jin et al., Proc. Natl. Acad. Sci. USA 87:3319-3323 (1990); Blank et al., Nature 337:187-189 (1989); Lanier et al., Nature 342:803-805 (1989); Kurosaki and Ravetch, Nature 342:805-807 (1989); Hibbs et al., Science 246:1608-1611 (1989); Anderson et al., Proc. Natl. Acad. Sci. USA 87:2274-2278 (1990); and Irving and Weiss, Cell 64: 891-901 (1991)).

15 In drawing parallels between the murine and human low affinity Fc receptor families, however, it has become clear that the human FcR γ IIA and C isoforms have no murine counterpart. In part because of this, their function has yet to be defined.

20 Because humoral agents based on CD4 alone may have limited utility in vivo, previous work explored the possibility of augmenting cellular immunity to HIV. Preparations of protein chimeras in which the extracellular domain of CD4 is fused to the transmembrane and/or intracellular domains of T cell receptor, IgG Fc
25 receptor, or B cell receptor signal transducing elements have been identified (U.S.S.N. 07/847,566 and 07/665,961, hereby incorporated by reference). Cytolytic T cells expressing chimeras which include an extracellular CD4
30 domain show potent MHC-independent destruction of cellular targets expressing HIV envelope proteins. An extremely important and novel component of this approach has been the identification of single T cell receptor, Fc receptor, and B cell receptor chains whose aggregation
35 suffices to initiate the cellular response. One

- 9 -

particularly useful application of this approach has been the invention of chimeras between CD4 and ζ , η , or γ that direct cytolytic T lymphocytes to recognize and kill cells expressing HIV gp120 (U.S.S.N. 07/847,566 and 5 07/665,961, hereby incorporated by reference).

Summary of the Invention

In general, the invention features a method of directing a cellular immune response against an HIV-infected cell in a mammal. The method involves
10 administering to the mammal an effective amount of therapeutic cells, the therapeutic cells expressing a membrane-bound, proteinaceous chimeric receptor comprising (a) an extracellular portion which includes a fragment of CD4 which is capable of specifically
15 recognizing and binding the HIV-infected cell but which does not mediate HIV infection and (b) an intracellular portion which is capable of signalling the therapeutic cell to destroy the receptor-bound HIV-infected cell.

In a related method, the invention features the
20 use of therapeutic cells expressing a membrane-bound, proteinaceous chimeric receptor including (a) an extracellular portion which includes a fragment of CD4 which is capable of specifically recognizing and binding the HIV-infected cell but which does not mediate HIV
25 infection and (b) an intracellular portion which is capable of signalling the therapeutic cell to destroy the receptor-bound HIV-infected cell in the manufacture of a medicament for the treatment of HIV-related diseases.

In a second aspect, the invention features a cell
30 which expresses a proteinaceous membrane-bound chimeric receptor which comprises (a) an extracellular portion which includes a fragment of CD4 which is capable of specifically recognizing and binding the HIV-infected cell but which does not mediate HIV infection and (b) an

- 10 -

intracellular portion which is capable of signalling the therapeutic cell to destroy the receptor-bound HIV-infected cell.

In preferred embodiments of both aspects, the CD4 fragment is amino acids 1-394 of CD4 or is amino acids 1-200 of CD4; the CD4 fragment is separated from the intracellular portion by the CD7 transmembrane domain shown in Fig. 26 or by the hinge, CH2, and CH3 domains of the human IgG1 molecule shown in Fig. 25; the receptor includes a CD7 transmembrane portion; the receptor includes a CD5 transmembrane portion; the receptor includes a CD34 transmembrane portion; the CD4 fragment is separated from the therapeutic cell membrane by one or more proteinaceous alpha helices; the CD4 fragment is separated from the therapeutic cell membrane by at least 48 angstroms or by at least 72 angstroms; the intracellular portion is the signal-transducing portion of a T cell receptor protein (for example, ζ), a B cell receptor protein, or an Fc receptor protein; and the therapeutic cells are selected from the group consisting of: (a) T lymphocytes; (b) cytotoxic T lymphocytes; (c) natural killer cells; (d) neutrophils; (e) granulocytes; (f) macrophages; (g) mast cells; (h) HeLa cells; and (i) embryonic stem cells (ES).

In other aspects, the invention features DNA encoding a chimeric receptor of the invention; and a vector including that chimeric receptor DNA.

Although the specific embodiment of the present invention is a chimera between CD4 and zeta, any receptor chain having a similar function to these molecules, e.g., in granulocytes or B lymphocytes, could be used for the purposes disclosed here. The distinguishing features of a desirable immune cell trigger molecule comprises the ability to be expressed autonomously (i.e., as a single chain), the ability to be fused to an extracellular CD4

- 11 -

domain such that the resultant chimera is present on the surface of a therapeutic cell, and the ability to initiate cellular effector programs upon aggregation secondary to encounter with a target ligand.

5 At present the most convenient method for delivery of the chimeras to immune system cells is through some form of genetic therapy. However reconstituting immune system cells with chimeric receptors by mixture of the cells with suitably solubilized purified chimeric protein
10 would also result in the formation of an engineered cell population capable of responding to HIV-infected targets. Similar approaches have been used, for example, to introduce the CD4 molecule into erythrocytes for therapeutic purposes. In this case the engineered cell
15 population would not be capable of self renewal.

 The present invention relates to functional and simplified chimeras between CD4 fragments and T cell receptor, B cell receptor, and Fc receptor subunits which are capable of directing immune cells to recognize and
20 lyse HIV-infected cells. The method for directing the cellular response in a mammal comprises administering an effective amount of therapeutic cells (for example, cytotoxic T lymphocytes) to the mammal, the cells being capable of recognizing and destroying the HIV-infected
25 cell.

 The invention also includes the chimeric receptor proteins which direct the cytotoxic T lymphocytes to recognize and lyse HIV-infected cells, the host cells transformed with a vector comprising the chimeric
30 receptors, and antibodies directed against the chimeric receptors.

 These and other non-limiting embodiments of the present invention will be apparent to those of skill from the following detailed description of the invention.

- 12 -

In the following detailed description, reference will be made to various methodologies known to those of skill in the art of molecular biology and immunology. Publications and other materials setting forth such known
5 methodologies to which reference is made are incorporated herein by reference in their entireties as though set forth in full.

Standard reference works setting forth the general principles of recombinant DNA technology include Watson
10 et al., Molecular Biology of the Gene, Volumes I and II, the Benjamin/Cummings Publishing Company, Inc., publisher, Menlo Park, CA (1987); Darnell et al., Molecular Cell Biology, Scientific American Books, Inc., Publisher, New York, N.Y. (1986); Lewin, Genes II, John
15 Wiley & Sons, publishers, New York, N.Y. (1985); Old et al., Principles of Gene Manipulation: An Introduction to Genetic Engineering, 2d edition, University of California Press, publisher, Berkeley, CA (1981); Maniatis et al., Molecular Cloning: A Laboratory Manual, 2nd Ed. Cold
20 Spring Harbor Laboratory, publisher, Cold Spring Harbor, NY (1989); and Ausubel et al., Current Protocols in Molecular Biology, Wiley Press, New York, NY (1989).

DEFINITIONS

By "cloning" is meant the use of in vitro
25 recombination techniques to insert a particular gene or other DNA sequence into a vector molecule.

By "cDNA" is meant complementary or copy DNA produced from an RNA template by the action of RNA-dependent DNA polymerase (reverse transcriptase). Thus a
30 "cDNA clone" means a duplex DNA sequence complementary to an RNA molecule of interest, carried in a cloning vector.

By "cDNA library" is meant a collection of recombinant DNA molecules containing cDNA inserts which comprise DNA copies of mRNA being expressed by the cell

- 13 -

at the time the cDNA library was made. Such a cDNA library may be prepared by methods known to those of skill, and described, for example, in Ausubel et al., supra and Maniatis et al., supra. Generally, RNA is
5 first isolated from the cells of an organism from whose genome it is desired to clone a particular gene. Preferred for the purpose of the present invention are mammalian, and particularly human, lymphocytic cell lines. A presently preferred vector for this purpose is
10 the vaccinia virus WR strain.

By "vector" is meant a DNA molecule, derived, e.g., from a plasmid, bacteriophage, or mammalian or insect virus, into which fragments of DNA may be inserted or cloned. A vector will contain one or more unique
15 restriction sites and may be capable of autonomous replication in a defined host or vehicle organism such that the cloned sequence is reproducible. Thus, by "DNA expression vector" is meant any autonomous element capable of directing the synthesis of a recombinant
20 peptide. Such DNA expression vectors include bacterial plasmids and phages and mammalian and insect plasmids and viruses.

By "substantially pure" is meant a compound, e.g., a protein, a polypeptide, or an antibody, that is
25 substantially free of the components that naturally accompany it. Generally, a compound is substantially pure when at least 60%, more preferably at least 75%, and most preferably at least 90% of the total material in a sample is the compound of interest. Purity can be
30 measured by any appropriate method, e.g., column chromatography, polyacrylamide gel electrophoresis, or HPLC analysis. In the context of a nucleic acid, "substantially pure" means a nucleic acid sequence, segment, or fragment that is not immediately contiguous
35 with (i.e., covalently linked to) both of the coding

- 14 -

sequences with which it is immediately contiguous (i.e., one at the 5' end and one at the 3' end) in the naturally occurring genome of the organism from which the DNA of the invention is derived.

5 A "fragment" of a molecule, such as any of the cDNA sequences of the present invention, is meant to refer to any contiguous nucleotide subset of the molecule. An "analog" of a molecule is meant to refer to a non-natural molecule substantially similar to either
10 the entire molecule or a fragment thereof. A molecule is said to be "substantially similar" to another molecule if the sequence of amino acids in both molecules is substantially the same. Substantially similar amino acid molecules will possess a similar biological activity. As
15 used herein, a molecule is said to be a "chemical derivative" of another molecule when it contains chemical moieties not normally a part of the molecule. Such moieties may improve the molecule's solubility, absorption, biological half life, etc. The moieties may
20 alternatively decrease the toxicity of the molecule, eliminate or attenuate any undesirable side effect of the molecule, etc. Moieties capable of mediating such effects are disclosed, for example, in Remington's Pharmaceutical Sciences, 16th ed., Mack Publishing Co., Easton, Penn.
25 (1980).

 A "functional derivative" of a receptor chimera gene of the present invention is meant to include "fragments" or "analogues" of the gene, which are "substantially similar" in nucleotide sequence, and which
30 encode a molecule possessing similar activity to, for example, a T cell, B cell, or Fc receptor chimera. Most preferably, the derivative possesses 90%, more preferably, 70%, and preferably 40% of the wild-type receptor chimera's activity. The activity of a
35 functional chimeric receptor derivative includes specific

- 15 -

binding (with its extracellular CD4 portion) to an HIV-infected cell and resultant destruction of that cell; in addition, the chimeric receptor does not render the receptor-bearing cell susceptible to HIV infection.

- 5 Chimeric receptor activity may be tested using, e.g., any of the assays described herein.

A DNA sequence encoding the CD4 receptor chimera of the present invention, or its functional derivatives, may be recombined with vector DNA in accordance with
10 conventional techniques, including blunt-ended or staggered-ended termini for ligation, restriction enzyme digestion to provide appropriate termini, filling in of cohesive ends as appropriate, alkaline phosphatase treatment to avoid undesirable joining, and ligation with
15 appropriate ligases. Techniques for such manipulations are disclosed by Maniatis, T., et al., supra, and are well known in the art.

A nucleic acid molecule, such as DNA, is said to be "capable of expressing" a polypeptide if it contains
20 nucleotide sequences which contain transcriptional and translational regulatory information and such sequences are "operably linked" to nucleotide sequences which encode the polypeptide. An operable linkage is a linkage in which the regulatory DNA sequences and the DNA
25 sequence sought to be expressed are connected in such a way as to permit gene expression. The precise nature of the regulatory regions needed for gene expression may vary from organism to organism, but shall in general include a promoter region which, in prokaryotes, contains
30 both the promoter (which directs the initiation of RNA transcription) as well as the DNA sequences which, when transcribed into RNA, will signal the initiation of protein synthesis. Such regions will normally include those 5'-non-coding sequences involved with initiation of

- 16 -

transcription and translation, such as the TATA box, capping sequence, CAAT sequence, and the like.

If desired, the non-coding region 3' to the gene sequence coding for the protein may be obtained by the
5 above-described methods. This region may be retained for its transcriptional termination regulatory sequences, such as termination and polyadenylation. Thus, by retaining the 3'-region naturally contiguous to the DNA sequence coding for the protein, the transcriptional
10 termination signals may be provided. Where the transcriptional termination signals are not satisfactorily functional in the expression host cell, then a 3' region functional in the host cell may be substituted.

15 Two DNA sequences (such as a promoter region sequence and a CD4-receptor chimera encoding sequence) are said to be operably linked if the nature of the linkage between the two DNA sequences does not (1) result in the introduction of a frame-shift mutation, (2)
20 interfere with the ability of the promoter region sequence to direct the transcription of the receptor chimera gene sequence, or (3) interfere with the ability of the receptor chimera gene sequence to be transcribed by the promoter region sequence. A promoter region would
25 be operably linked to a DNA sequence if the promoter were capable of effecting transcription of that DNA sequence. Thus, to express the protein, transcriptional and translational signals recognized by an appropriate host are necessary.

30 The present invention encompasses the expression of a CD4-receptor chimera protein (or a functional derivative thereof) in either prokaryotic or eukaryotic cells, although eukaryotic (and, particularly, human lymphocyte) expression is preferred.

- 17 -

Antibodies according to the present invention may be prepared by any of a variety of methods. For example, cells expressing the CD4-receptor chimera protein, or a functional derivative thereof, can be administered to an animal in order to induce the production of sera containing polyclonal antibodies that are capable of binding the chimera.

In a preferred method, antibodies according to the present invention are monoclonal antibodies. Such monoclonal antibodies can be prepared using hybridoma technology (Kohler et al., Nature 256:495 (1975); Kohler et al., Eur. J. Immunol. 6:511 (1976); Kohler et al., Eur. J. Immunol. 6:292 (1976); Hammerling et al., In: Monoclonal Antibodies and T-Cell Hybridomas, Elsevier, N.Y., pp. 563-684 (1981)). In general, such procedures involve immunizing an animal with the CD4-receptor chimera antigen. The splenocytes of such animals are extracted and fused with a suitable myeloma cell line. Any suitable myeloma cell line may be employed in accordance with the present invention. After fusion, the resulting hybridoma cells are selectively maintained in HAT medium, and then cloned by limiting dilution as described by Wands et al. (Gastroenterology 80:225-232 (1981)). The hybridoma cells obtained through such a selection are then assayed to identify clones which secrete antibodies capable of binding the chimera.

Antibodies according to the present invention also may be polyclonal, or, preferably, region specific polyclonal antibodies.

Antibodies against the CD4-receptor chimera according to the present invention may be used to monitor the amount of chimeric receptor (or chimeric receptor-bearing cells) in a patient. Such antibodies are well suited for use in standard immunodiagnostic assay known in the art, including such immunometric or "sandwich"

- 18 -

assays as the forward sandwich, reverse sandwich, and simultaneous sandwich assays. The antibodies may be used in any number of combinations as may be determined by those of skill without undue experimentation to effect
5 immunoassays of acceptable specificity, sensitivity, and accuracy.

Standard reference works setting forth general principles of immunology include Roitt, Essential Immunology, 6th ed., Blackwell Scientific Publications, Publisher, Oxford (1988); Kimball, Introduction to Immunology, 2d ed., Macmillan Publishing Co., Publisher, New York (1986); Roitt et al., Immunology, Gower Medical Publishing Ltd., Publisher, London, (1985); Campbell, "Monoclonal Antibody Technology," in Burdon et al., eds.,
15 Laboratory Techniques in Biochemistry and Molecular Biology, Volume 13, Elsevier, Publisher, Amsterdam (1984); Klein, Immunology: The Science of Self-Nonself Discrimination, John Wiley & Sons, Publisher, New York (1982); and Kennett et al., eds., Monoclonal Antibodies,
20 Hybridoma: A New Dimension In Biological Analyses, Plenum Press, Publisher, New York (1980).

By "detecting" it is intended to include determining the presence or absence of a substance or quantifying the amount of a substance. The term thus
25 refers to the use of the materials, compositions, and methods of the present invention for qualitative and quantitative determinations.

The antibodies and substantially purified antigen of the present invention are ideally suited for the
30 preparation of a kit. Such a kit may comprise a carrier means being compartmentalized to receive in close confinement therewith one or more container means such as vials, tubes and the like, each of said container means comprising the separate elements of the assay to be used.

- 19 -

The types of assays which can be incorporated in kit form are many, and include, for example, competitive and non-competitive assays. Typical examples of assays which can utilize the antibodies of the invention are

5 radioimmunoassays (RIA), enzyme immunoassays (EIA), enzyme-linked immunoadsorbent assays (ELISA), and immunometric, or sandwich, immunoassays.

By the term "immunometric assay" or "sandwich immunoassay," it is meant to include simultaneous

10 sandwich, forward sandwich, and reverse sandwich immunoassays. These terms are well understood by those skilled in the art. Those of skill will also appreciate that antibodies according to the present invention will be useful in other variations and forms of assays which

15 are presently known or which may be developed in the future. These are intended to be included within the scope of the present invention.

By "specifically recognizes and binds" is meant that the antibody recognizes and binds the chimeric

20 receptor polypeptide but does not substantially recognize and bind other unrelated molecules in a sample, e.g., a biological sample.

By "therapeutic cell" is meant a cell which has been transformed by a CD4-receptor chimera of the

25 invention so that it is capable of recognizing and destroying an HIV-infected cell; preferably such therapeutic cells are cells of the hematopoietic system.

By "extracellular" is meant having at least a portion of the molecule exposed at the cell surface. By

30 "intracellular" is meant having at least a portion of the molecule exposed to the therapeutic cell's cytoplasm. By "transmembrane" is meant having at least a portion of the molecule spanning the plasma membrane. An "extracellular portion", an "intracellular portion" and a "transmembrane

35 portion", as used herein, may include flanking amino acid

- 20 -

sequences which extend into adjoining cellular compartments.

By "oligomerize" is meant to complex with other proteins to form dimers, trimers, tetramers, or other
5 higher order oligomers. Such oligomers may be homo-oligomers or hetero-oligomers. An "oligomerizing portion" is that region of a molecule which directs complex (i.e., oligomer) formation.

By "cytolytic" is meant to be capable of
10 destroying a cell (e.g., an HIV-infected cell) or to be capable of destroying an infective agent (e.g., an HIV virus).

By "immunodeficiency virus" is meant a retrovirus that, in wild-type form, is capable of infecting T4 cells
15 of a primate host and possesses a viral morphogenesis and morphology characteristic of the lentivirus subfamily. The term includes, without limitation, all variants of HIV and SIV, including HIV-1, HIV-2, SIVmac, SIVagm, SIVmnd, SIVsmm, SIVman, SIVmand, and SIVcpz.

20 By "MHC-independent" is meant that the cellular cytolytic response does not require the presence of an MHC class II antigen on the surface of the targeted cell.

By a "functional cytolytic signal-transducing derivative" is meant a functional derivative (as defined
25 above) which is capable of directing at least 40%, more preferably 70%, or most preferably at least 90% of the biological activity of the wild type molecule. As used herein, a "functional cytolytic signal-transducing derivative" may act by directly signaling the therapeutic
30 cell to destroy a receptor-bound agent or cell (e.g., in the case of an intracellular chimeric receptor portion) or may act indirectly by promoting oligomerization with cytolytic signal transducing proteins of the therapeutic cell (e.g., in the case of a transmembrane domain). Such

- 21 -

derivatives may be tested for efficacy, e.g., using the in vitro assays described herein.

By a "functional HIV envelope-binding derivative" is meant a functional derivative (as defined above) which is capable of binding any HIV envelope protein. Functional derivatives may be identified using, e.g., the in vitro assays described herein.

THERAPEUTIC ADMINISTRATION

The transformed cells of the present invention are used for immunodeficiency virus therapy. Current methods of administering such transformed cells involve adoptive immunotherapy or cell-transfer therapy. These methods allow the return of the transformed immune-system cells to the bloodstream. Rosenberg, Scientific American 62 (May 1990); Rosenberg et al., The New England Journal of Medicine 323(9):570 (1990).

The pharmaceutical compositions of the invention may be administered to any animal which may experience the beneficial effects of the compounds of the invention. Foremost among such animals are humans, although the invention is not intended to be so limited.

Detailed Description

The drawings will first be described.

Brief Description of the Drawings

FIG. 1A presents the amino acid sequence about the site of fusion between CD4 (residues 1-369) and different receptor chains. The underlined sequence shows the position of the amino acids encoded within the BamHI site used for fusion construction. The beginning of the transmembrane domain is marked with a vertical bar. The η sequence is identical to the ζ sequence at the amino terminus, but diverges at the carboxyl terminus (Jin et

- 22 -

al., Proc. Natl. Acad. Sci. USA 87:3319-3323 (1990)).

FIG. 1B presents flow cytometric analysis of surface expression of CD4, CD4:ζ, CD4:γ and CD4:η in CV1 cells. Cells were infected with virus expressing CD4 chimeras or
5 CD16_{PI}, incubated for 9 hours at 37°C, and stained with phycoerythrin-conjugated anti-CD4 MAb Leu3A.

FIG. 2 shows surface expression of CD16_{TM} following coinfection of CD16_{TM} alone (dense dots), or coinfecting with virus expressing CD4:γ (dashes) or CD4:ζ
10 (solid line). Sparse dots, cells infected with CD4:ζ alone, stained with 3G8 (Fleit et al., Proc. Natl. Acad. Sci. USA 79:3275-3279 (1982)) (anti-CD16 MAb).

FIG. 3 shows surface expression of CD16_{TM} following coinfection by viruses expressing CD16_{TM} and the
15 following ζ chimeras: CD4:ζ (thick line), CD4:ζ C11G (solid line); CD4:ζ (dashed line); CD4:ζ C11G/D15G (dense dots); no coinfection (CD16_{TM} alone, sparse dots). Cells were incubated with anti-CD16 MAb 3G8 and phycoerythrin-conjugated Fab'₂ goat antibodies to mouse IgG. The level
20 of expression of the ζ chimeras was essentially identical for the different mutants analyzed, and coinfection of cells with viruses expressing CD16_{TM} and ζ chimeras did not appreciably alter surface expression of the chimeras.

FIG. 4A-D shows increased intracellular free
25 calcium ion follows crosslinking of mutant ζ chimeras in a T cell line. Jurkat E6 cells (Weiss et al., J. Immunol. 133:123-128 (1984)) were infected with recombinant vaccinia viruses and analyzed by flow cytometry. The results shown are for the gated CD4⁺
30 population, so that only cells expressing the relevant chimeric protein are analyzed. The mean ratio of violet to blue Indo-1 fluorescence reflects the intracellular free calcium concentration in the population as a whole and the percentage of responding cells reflects the
35 fraction of cells which exceed a predetermined threshold

- 23 -

ratio (set so that 10% of untreated cells are positive).
FIG. 4A and FIG. 4B show Jurkat cells expressing CD4:ζ
(solid line) or CD16:ζ (dashed line) which were exposed
to anti-CD4 MAb Leu3a (phycoerythrin conjugate), followed
5 by crosslinking with goat antibody to mouse IgG. The
dotted line shows the response of uninfected cells to
anti-CD3 MAb OKT3. FIGS. 4C and 4D show Jurkat cells
expressing CD4:ζD15G (solid line); CD4:ζC11G/D15G
(dashes); or CD4:ζC11G (dots) which were treated and
10 analyzed as in FIGS. 4A and 4B.

FIG. 5A-C shows that CD4:ζ, CD4:η, and CD4:γ
receptors allow cytolytic T lymphocytes (CTL) to kill
targets expressing HIV-1 gp120/41. FIG. 5A: solid
circles, CTL expressing CD4:ζ incubated with HeLa cells
15 expressing gp120/41; open circles, CTL expressing CD4:ζ
incubated with uninfected HeLa cells; solid squares,
uninfected CTL incubated with HeLa cells expressing
gp120/41; open squares, uninfected CTL incubated with
uninfected HeLa cells. FIG. 5B: solid circles, CTL
20 expressing CD4:η incubated with HeLa cells expressing
gp120/41; open circles, CTL expressing CD4:γ incubated
with HeLa cells expressing gp120/41; open squares, CTL
expressing the C11G/D15G double mutant CD4:ζ chimera
incubated with HeLa cells expressing gp120/41. FIG. 5C:
25 Flow cytometric analysis of CD4 expression by the CTL
used in Fig. 5B. To correct the target to effector
ratios the percent of cells expressing CD4 chimera was
determined by subtracting the scaled negative
(uninfected) population by histogram superposition; for
30 comparative purposes in this figure the uninfected cells
were assigned an arbitrary threshold which gives roughly
the same fraction positive for the other cell populations
as would histogram subtraction.

FIG. 6A-B shows specificity of CD4-directed
35 cytotoxicity. FIG. 6A: solid circles, CTL expressing CD4:ζ

- 24 -

incubated with HeLa cells expressing CD16_{p1}; open circles, CTL expressing CD4 incubated with HeLa cells expressing gp120; solid squares, CTL expressing CD16:ζ incubated with HeLa cells expressing gp120/41; open squares, CTL
5 expressing CD16_{p1} incubated with HeLa cells expressing gp120/41. FIG. 6B: solid circles, CTL expressing CD4:ζ incubated with Raji (MHC class II⁺) cells; open circles, uninfected CTL cells incubated with RJ2.2.5 (MHC class II⁻ Raji mutant) cells; solid squares, uninfected CTL
10 incubated with Raji (MHC class II⁺) cells; open squares, CTL expressing CD4:ζ incubated with RJ2.2.5 (MHC class II⁻) cells. The ordinate scale is expanded.

FIG. 7A-B shows characterization of the CD16:ζ chimeric receptor. FIG. 7A is a schematic diagram of the
15 CD16:ζ fusion protein. The extracellular portion of the phosphatidylinositol-linked form of monomeric CD16 was joined to dimeric ζ just external to the transmembrane domain. The protein sequence at the fusion junction is shown at the bottom. FIG. 7B shows a flow cytometric
20 analysis of calcium mobilization following crosslinking of the CD16:ζ chimera in either a TCR positive or TCR negative cell line. The mean ratio of violet to blue fluorescence (a measure of relative calcium ion concentration) among cell populations treated with
25 antibodies at time 0 is shown. Solid squares, the response of Jurkat cells to anti-CD3 MAb OKT3; solid triangles, the response of CD16:ζ to anti-CD16 MAb 3G8 crosslinking in the REX33A TCR⁻ mutant; open squares, the response to CD16:ζ crosslinking in the Jurkat TCR⁻ mutant
30 line JRT3.T3.5; open triangles, the response to CD16:ζ crosslinking in Jurkat cells; crosses, the response to nonchimeric CD16 in Jurkat cells; and dots, the response to nonchimeric CD16 in the REX33A TCR⁻ cell line.

FIG. 8A-B shows deletion analysis of cytolytic
35 potential. FIG. 8A shows the locations of the ζ deletion

- 25 -

endpoints. Here as elsewhere mutations in ζ are represented by the original residue-location-mutant residue convention, so that D66*, for example, denotes replacement of Asp-66 by a termination codon. FIG. 8B shows cytolysis assay results of undeleted CD16: ζ and salient ζ deletions. Hybridoma cells expressing surface antibody to CD16 were loaded with ^{51}Cr and incubated with increasing numbers of human cytolytic lymphocytes (CTL) infected with vaccinia recombinants expressing CD16: ζ chimeras. The percent of ^{51}Cr released is plotted as a function of the effector (CTL) to target (hybridoma) cell ratio (e/t). Solid circles, cytolysis mediated by cells expressing CD16: ζ (mfi 18.7); solid squares, cytolysis mediated by cells expressing CD16: ζ Asp66* (mfi 940.2); open squares, cytolysis mediated by cells expressing CD16: ζ Glu60* (mfi 16.0); open circles, cytolysis mediated by cells expressing CD16: ζ Tyr51* (mfi 17.4); solid triangles, cytolysis mediated by cells expressing CD16: ζ Phe34* (mfi 17.8); and open triangles, cytolysis mediated by cells expressing nonchimeric CD16 (mfi 591). Although in this experiment the expression of CD16: ζ Asp66* was not matched to that of the other fusion proteins, cytolysis by cells expressing CD16: ζ at equivalent levels in the same experiment gave results essentially identical to those shown by cells expressing CD16: ζ Asp66.

FIG. 9A-D shows that elimination of the potential for transmembrane interactions reveals a short ζ segment capable of mediating cytolysis. FIG. 9A is a schematic diagram of the monomeric bipartite and tripartite chimeras. At the top is the CD16: ζ construct truncated at residue 65 and lacking transmembrane Cys and Asp residues. Below are the CD16:CD5: ζ and CD16:CD7: ζ constructs and related controls. The peptide sequences of the intracellular domains are shown below. FIG. 9B

- 26 -

shows the cytolytic activity of monomeric chimera deletion mutants. The cytolytic activity of cells expressing CD16:ζ (solid circles; mfi 495) was compared to that of cells expressing CD16:ζAsp66* (solid squares; mfi 527) or the mutants CD16:ζCys11Gly/Asp15Gly/Asp66*, (open squares; mfi 338) and CD16:ζCys11Gly/Asp15Gly/Glu60* (filled triangles; mfi 259). FIG. 9C shows the cytolytic activity mediated by tripartite fusion proteins. Solid triangles, CD16:ζAsp66*; open squares, CD16:5:ζ(48-65); solid squares CD16:7:ζ(48-65); open triangles, CD16:7:ζ(48-59); open circles, CD16:5; solid circles, CD16:7. FIG. 9D shows calcium mobilization by mutant and tripartite chimeras in the TCR negative Jurkat JRT3.T3.5 mutant cell line. Open circles, response of cells expressing dimeric CD16:ζAsp66*; solid squares, response of cells expressing CD16:ζCys11Gly/Asp15Gly/Asp66*; open squares, response of cells expressing CD16:ζCys11Gly/Asp15Gly/Glu60*; solid triangles, response of cells expressing CD16:7:ζ(48-65); and open triangles, response of cells expressing CD16:ζ(48-59).

FIG. 10A-F shows the contribution of individual amino acids to the activity of the 18 residue cytolytic signal-transducing motif. FIGS. 10A and 10B show cytolytic activity and FIG. 10C shows calcium ion mobilization mediated by chimeras bearing point mutations near the carboxyl terminal tyrosine (Y62). FIGS. 10A and 10B represent data collected on cells expressing low and high amounts, respectively, of the CD16:ζ fusion proteins. Identical symbols are used for the calcium mobilization and cytotoxicity assays, and are shown in one letter code at right. Solid circles, cells expressing CD16:ζ (mfi in A, 21; B, 376); solid squares, cells expressing CD16:7:ζ(48-65) (mfi A, 31; B, 82); open squares, CD16:7:ζ(48-65)Glu60Gln (mfi A, 33; B, 92),

- 27 -

crosses, CD16:7:ζ(48-65)Asp63Asn (mfi A, 30; B, 74);
solid triangles, CD16:7:ζ(48-65)Tyr62Phe (mfi A, 24; B,
88); open circles, CD16:7:ζ(48-65)Glu61Gln (mfi A, 20; B,
62); and open triangles, CD16:7:ζ(48-65)Tyr62Ser (mfi B,
5 64). FIGS. 10D and 10E show cytolytic activity and FIG.
10F shows calcium ion mobilization by chimeras bearing
point mutations near the amino terminal tyrosine (Y51).
Identical symbols are used for the calcium mobilization
and cytotoxicity assays and are shown at right. Solid
10 circles, cells expressing CD16:ζ (mfi in D, 21.2; in E,
672); solid squares, cells expressing CD16:7:ζ(48-65)
(mfi D, 31.3; E, 179); solid triangles, CD16:7:ζ(48-
65)Asn48Ser (mfi D, 22.4; E, 209); open squares,
CD16:7:ζ(48-65)Leu50Ser (mfi D, 25.0; E, 142); and open
15 triangles, CD16:7:ζ(48-65)Tyr51Phe (mfi D, 32.3; E, 294).

FIG. 11A-B shows alignment of internal repeats of
ζ and comparison of their ability to support cytotoxicity.
FIG. 11A is a schematic diagram of chimeras formed by
dividing the ζ intracellular domain into thirds and
20 appending them to the transmembrane domain of a CD16:7
chimera. The sequences of the intracellular domains are
shown below, with shared residues boxed, and related
residues denoted by asterisks. FIG. 11B shows the
cytotoxic potency of the three ζ subdomains. Solid
25 circles, cells expressing CD16:ζ (mfi 476); solid
squares, CD16:7:ζ(33-65) (mfi 68); open squares,
CD16:7:ζ(71-104) (mfi 114); and solid triangles,
CD16:7:ζ(104-138) (mfi 104).

FIG. 12 is a schematic diagram of the CD16:FcRγII
30 chimeras.

FIG. 13A-B shows calcium mobilization following
crosslinking of CD4:FcRγII and CD16:FcRγII chimeras.
FIG. 13A shows the ratio of violet to blue fluorescence
emitted by cells loaded with the calcium sensitive
35 fluorophore Indo-1 shown as a function of time following

- 28 -

crosslinking of the CD16 extracellular domain with antibodies. FIG. 13B shows a similar analysis of the increase in ratio of violet to blue fluorescence of cells bearing CD4:FcRγII chimeras, following crosslinking with 5 antibodies.

FIG. 14A-B shows cytolysis assays of CD4:FcRγII and CD16:FcRγII chimeras. FIG. 14A shows the percent of ⁵¹Cr released from anti-CD16 hybridoma (target) cells when the cells are exposed to increasing numbers of cytotoxic 10 T lymphocytes expressing CD16:FcRγII chimeras (effector cells). FIG. 14B shows a similar analysis of cytotoxicity mediated by CD4:FcRγII chimeras against target cells expressing HIV envelope glycoproteins.

FIG. 15A-E shows identification of residues in the 15 FcRγII A tail which are important for cytolysis. FIG. 15A is a schematic diagram of the deletion constructs. FIGS. 15B and 15C shows calcium mobilization and cytolysis by carboxyl-terminal deletion variants of CD16:FcRγII A. FIGS. 15D and 15E show calcium 20 mobilization and cytolysis by tripartite chimeras bearing progressively less of the amino terminus of the intracellular tail of CD16:FcRγII A.

FIG. 16 (SEQ ID NO: 24) shows the amino acid sequence of the CD3 delta receptor protein; the boxed 25 sequence represents a preferred cytolytic signal transducing portion.

FIG. 17 (SEQ ID NO: 25) shows the amino acid sequence of the T3 gamma receptor protein; the boxed 30 sequence represents a preferred cytolytic signal transducing portion.

FIG. 18 (SEQ ID NO: 26) shows the amino acid sequence of the mbl receptor protein; the boxed sequence represents a preferred cytolytic signal transducing portion.

- 29 -

FIG. 19 (SEQ ID NO: 27) shows the amino acid sequence of the B29 receptor protein; the boxed sequence represents a preferred cytolytic signal transducing portion.

5 FIG. 20A-E shows a schematic diagram of the CD4 chimeras. Molecule "A" is CD4(D1-D4):Ig:CD7; molecule "B" is CD4(D1,D2):Ig:CD7; molecule "C" is CD4(D1-D4):Ig:CD7:ζ; molecule "D" is CD4(D1,D2):Ig:CD7:ζ; and molecule "E" is CD4:ζ. The extracellular domain of the
10 human CD4 molecule corresponding to amino acids 1-394 of the precursor was joined by a BamHI site to the hinge, CH1, and CH2 domains of human IgG1 as described previously (Zettlmeissl et al., DNA Cell Biol. 9:347 (1990)) except that a cDNA version of the human Ig
15 sequences was used to allow expression in vaccinia virus recombinants. The two-domain version of the CD4 chimeras were created by insertion of a BamHI adaptor at the unique NheI site (corresponding to amino acid 200) in the CD4 precursor cDNA. The membrane attachment sequences
20 consisted of 22 residues from the first exon of human membrane-bound IgG1 followed by CD7 residues 146-203. Amino acids 55 through 163 of ζ served as the trigger motif of the tetrapartite constructs (C and D). In tetrapartite constructs containing the ζ chain,
25 intracellular expression of ζ was documented with a commercially available antibody against the intracellular domain (Coulter).

FIG. 21 shows cytolysis of target cells expressing the HIV-1 envelope glycoprotein mediated by the cytotoxic
30 T-cell clone, WH3, expressing various CD4-derived chimeras as effector molecules. For cytotoxicity assays, the human CD8⁺ CD4⁻ HLA B44 restricted T cell line, WH3, was maintained in IMDM supplemented with 10% human serum as previously described herein. The cells were
35 stimulated with gamma-irradiated (3000rad) B44-bearing

- 30 -

mononuclear cells and phytohemagglutinin (PHA) at $1\mu\text{g/ml}$. After one day of stimulation, the PHA was diluted to $0.5\mu\text{g/ml}$ by addition of fresh medium; after 3 days the medium was changed completely. Cells were grown for at least 10 days before use in cytotoxicity assays. Cells were infected with the appropriate recombinant vaccinia viruses as described herein for vPE16. Infections were allowed to proceed for an additional 3-4 hours in complete medium after which cells were harvested by centrifugation and resuspended at a density of $1 \times 10^7/\text{ml}$. $100\mu\text{l}$ were added to each well of a U-bottom microtiter plate containing $100\mu\text{l}$ per well of complete medium and diluted in 2-fold serial steps. Two wells for each sample did not contain lymphocytes, to allow spontaneous chromium release and total chromium uptake to be measured. The target cells, HeLa subline S3 (HeLa-S3, ATCC) were infected as above in 10 cm dishes with vPE16. 10^6 infected cells were detached with PBS and 1mM EDTA, centrifuged and resuspended in $100\mu\text{l}$ of ^{51}Cr sodium chromate (1 mCi/ml in PBS) for 1 hour at 37°C and then washed three times with PBS. $100\mu\text{l}$ of labelled target cells were added to each well. The microtiter plate was spun at $750 \times g$ for 1 minute and incubated for 4 hours at 37°C . At the end of the incubation period, the cells in each well were resuspended by gentle pipetting, a sample removed to determine the total counts incorporated and the microtiter plate was spun at $750 \times g$ for 1 min. Aliquots ($100\mu\text{l}$) of the supernatant were removed and counted in a gamma ray scintillation counter. The effector:target ratio was corrected for the percent of cells infected as measured by flow cytometry.

FIG. 22 shows replication of HIV-1 in transfectant cell lines. Cell lines stably expressing wild type CD4 and various recombinant chimeras were established in a subline of the human embryonal kidney cell line 293. A

- 31 -

virus stock of the HIV-1 IIIB isolate was prepared with a titer of $\approx 10^6$ infectious particles/ml as measured by end-point dilution analysis using the human T-cell line C8166 as an indicator. Infections were carried out at an
5 approximate MOI of 1 for a period of 8-12 hours at 37°C. On the following day the cells were washed with PBS three times, trypsinized, replated in new dishes and the culture supernatant sampled for p24 titer (designated day 0). At 3-4 day intervals thereafter, cell culture
10 supernatants were collected and retained for p24 analysis. The cells were resupplied with fresh medium containing hygromycin B at a concentration of 100 $\mu\text{g/ml}$. Analysis of culture supernatants was carried out using a commercial ELISA-based HIV-1 p24 antigen assay kit
15 (Coulter) according to the instructions supplied by the manufacturer. Results are representative of two independent experiments of similar duration.

FIG. 23 shows the nucleic acid and amino acid sequence of the D1-D4 domains of CD4 (CD4 Bam).

20 FIG. 24 shows the nucleic acid and amino acid sequence of the D1-D2 domains of CD4 (CD4 Nhe).

FIG. 25 shows the nucleic acid and amino acid sequence of the hinge, CH2, and CH3 domains of human IgG1 (Igh23 Bam).

25 FIG. 26 shows the nucleic acid and amino acid sequence of the transmembrane domain of CD7 (TM7 Bam Mlu).

FIG. 27 shows the nucleic acid and amino acid sequence of the intracellular domain of zeta (Zeta Mlu
30 Not).

FIG. 28 shows the DNA sequence and primary amino acid sequence of a synthetic alpha helix.

- 32 -

EXAMPLE I

Constructi n of Human IgG1:R ceptor Chimeras

Human IgG1 heavy chain sequences were prepared by joining sequences in the C_H3 domain to a cDNA fragment
5 derived from the 3' end of the transmembrane form of the antibody mRNA. The 3' end fragment was obtained by polymerase chain reaction using a tonsil cDNA library as substrate, and oligonucleotides having the sequences:

CGC GGG GTG ACC GTG CCC TCC AGC AGC TTG GGC (SEQ
10 ID NO: 7) and

CGC GGG GAT CCG TCG TCC AGA GCC CGT CCA GCT CCC
CGT CCT GGG CCT CA (SEQ ID NO: 8),
corresponding to the 5' and 3' ends of the desired DNA
fragments respectively. The 5' oligo is complementary to
15 a site in the C_H1 domain of human IgG1, and the 3' oligo is complementary to a site just 5' of the sequences encoding the membrane spanning domain. The PCR product was digested with BstXI and BamHI and ligated between BstXI and BamHI sites of a semisynthetic IgG1 antibody
20 gene bearing variable and constant regions. Following the insertion of the BstXI to BamHI fragment, the amplified portions of the construct were replaced up to the SmaI site in C_H3 by restriction fragment interchange, so that only the portion between the SmaI site and the 3'
25 oligo was derived from the PCR reaction.

To create a human IgG1:ζ chimeric receptor, the heavy chain gene ending in a BamHI site was joined to the BamHI site of the ζ chimera described below, so that the antibody sequences formed the extracellular portion.
30 Flow cytometry of COS cells transfected with a plasmid encoding the chimera showed high level expression of antibody determinants when an expression plasmid encoding a light chain cDNA was cotransfected, and modest expression of antibody determinants when the light chain
35 expression plasmid was absent.

- 33 -

Similar chimeras including human IgG1 fused to η or γ (see below), or any signal-transducing portion of a T cell receptor or Fc receptor protein may be constructed generally as described above using standard techniques of molecular biology.

To create a single transcription unit which would allow both heavy and light chains to be expressed from a single promoter, a plasmid encoding a bicistronic mRNA was created from heavy and light chain coding sequences, and the 5' untranslated portion of the mRNA encoding the 78kD glucose regulated protein, otherwise known as grp78, or BiP. grp78 sequences were obtained by PCR of human genomic DNA using primers having the sequences:

CGC GGG CGG CCG CGA CGC CGG CCA AGA CAG CAC (SEQ ID NO: 9) and

CGC GTT GAC GAG CAG CCA GTT GGG CAG CAG CAG (SEQ ID NO: 10)

at the 5' and 3' ends respectively. Polymerase chain reactions with these oligos were performed in the presence of 10% dimethyl sulfoxide. The fragment obtained by PCR was digested with NotI and HincII and inserted between NotI and HpaI sites downstream from human IgG1 coding sequences. Sequences encoding a human IgG kappa light chain cDNA were then inserted downstream from the grp78 leader, using the HincII site and another site in the vector. The expression plasmid resulting from these manipulations consisted of the semisynthetic heavy chain gene, followed by the grp78 leader sequences, followed by the kappa light chain cDNA sequences, followed by polyadenylation signals derived from an SV40 DNA fragment. Transfection of COS cells with the expression plasmid gave markedly improved expression of heavy chain determinants, compared to transfection of plasmid encoding heavy chain determinants alone.

- 34 -

To create a bicistronic gene comprising a heavy chain/receptor chimera and a light chain, the upstream heavy chain sequences can be replaced by any chimeric heavy chain/ receptor gene described herein.

5

EXAMPLE II**Construction of CD4 Receptor Chimeras**

Human ζ (Weissman et al., Proc. Natl. Acad. Sci. USA 85:9709-9713 (1988b)) and γ (Küster et al., J. Biol. Chem. 265:6448-6452 (1990)) cDNAs were isolated by
10 polymerase chain reaction from libraries prepared from the HPB-ALL tumor cell line (Aruffo et al., Proc. Natl. Acad. Sci. USA 84:8573-8577 (1987b)) and from human natural killer cells, while η cDNA (Jin et al., Proc. Natl. Acad. Sci. USA 87:3319-3323 (1990)) was isolated
15 from a murine thymocyte library. ζ , η and γ cDNAs were joined to the extracellular domain of an engineered form of CD4 possessing a BamHI site just upstream of the membrane spanning domain (Aruffo et al., Proc. Natl. Acad. Sci. USA 84:8573-8577 (1987b); Zettlmeissl et al.,
20 DNA Cell Biol. 9:347-353 (1990)) which was joined to the BamHI site naturally present in the ζ and η cDNAs at a similar location a few residues upstream of the membrane spanning domain (SEQ ID NOS: 1, 3, 4 and 6). To form the fusion protein with γ a BamHI site was engineered into
25 the sequence at the same approximate location (Fig. 1; SEQ ID NO: 2 and 5). The gene fusions were introduced into a vaccinia virus expression plasmid bearing the E. coli gpt gene as a selectable marker, and inserted into the genome of the vaccinia WR strain by homologous
30 recombination and selection for growth in mycophenolic acid (Falkner et al., J. Virol. 62:1849-1854 (1988); Boyle et al., Gene 65:123-128 (1988)). Flow cytometric analysis showed that the vaccinia recombinants direct the abundant production of CD4: ζ and CD4: γ fusion proteins at

- 35 -

the cell surface, whereas the expression of CD4: η is substantially weaker (Fig. 1B). The latter finding is consistent with a recent report that transfection of an η cDNA expression plasmid into a murine hybridoma cell line gave substantially less expression than transfection of a comparable ζ expression plasmid (Clayton et al., J. Exp. Med. **172**:1243-1253 (1990)). Immunoprecipitation of cells infected with the vaccinia recombinants revealed that the fusion proteins form covalent dimers, unlike the naturally occurring CD4 antigen. The molecular masses of the monomeric CD4: ζ and CD4: γ fusion proteins and native CD4 were found to be 63, 55 and 53 kD respectively. The larger masses of the fusion proteins are approximately consistent with the greater length of the intracellular portion, which exceeds that of native CD4 by 75 (CD4: ζ) or 5 (CD4: γ) residues.

EXAMPLE III

CD4 Chimeras Can Associate With Other Receptor Chains

Cell surface expression of the macrophage/natural killer cell form of human Fc γ RIII (CD16_{TM}) on transfectants is facilitated by cotransfection with murine (Kurosaki et al., Nature **342**:805-807 (1989)) or human (Hibbs et al., Science **246**:1608-1611 (1989)) γ , as well as by human ζ (Lanier et al., Nature **342**:803-805 (1989)).

Consistent with these reports, expression of the chimeras also allowed surface expression of CD16_{TM} when delivered to the target cell either by cotransfection or by coinfection with recombinant vaccinia viruses (Fig. 2). The promotion of CD16_{TM} surface expression by ζ was more pronounced than promotion by γ (Fig. 2) in the cell lines examined, whereas native CD4 did not enhance CD16_{TM} surface expression.

- 36 -

EXAMPLE IV**Asp ζ Mutants Do Not Associate with Fc Receptor**

To create chimeras which would not associate with existing antigen or Fc receptors, mutant ζ fusion proteins which lacked either the intramembranous Asp or intramembranous Cys residue or both were prepared. Flow cytometry showed that the intensity of cell surface expression by the different mutant chimeras was not appreciably different from the unmutated precursor, and immunoprecipitation experiments showed that total expression by the chimeras was similar. As expected, the mutant chimeras lacking the transmembrane cysteine residue were found not to form disulfide linked dimers. The two mutant chimeras lacking Asp were incapable of supporting the surface expression of CD16TM, whereas the monomeric chimeras lacking Cys but bearing Asp allowed CD16_{TM} to be coexpressed, but at lower efficiency than the parental dimer (Fig. 3).

EXAMPLE V**Mutant Receptors Retain the Ability to Initiate a Calcium Response**

To determine whether crosslinking of the fusion proteins would allow the accumulation of free intracellular calcium in a manner similar to that known to occur with the T cell antigen receptor, cells of the human T cell leukemia line, Jurkat E6 (ATCC Accession Number TIB 152, American Type Culture Collection, Rockville, MD), were infected with the vaccinia recombinants and the relative cytoplasmic calcium concentration following crosslinking of the extracellular domain with antibodies was measured. Flow cytometric measurements were performed with cells loaded with the calcium sensitive dye Indo-1 (Grynkiewicz et al., J. Biol. Chem. 260:3340-3450 (1985); Rabinovitch et al., J.

- 37 -

Immunol. 137:952-961 (1986)). Figure 4A-D shows the results of calcium flux experiments with cells infected with CD4:ζ and the Asp⁻ and Cys⁻ mutants of ζ. Crosslinking of the chimeras, reproducibly increased intracellular calcium. CD4:η and CD4:γ similarly allowed accumulation intracellular calcium in infected cells. Jurkat cells express low levels of CD4 on the cell surface, however, crosslinking of the native CD4 in the presence or absence of CD16:ζ does not alter intracellular calcium levels (Fig. 4A-B).

EXAMPLE VI

CD4:ζ, η, and γ Chimeras Mediate Cytolysis of Targets Expressing HIV gp120/41

To determine whether the chimeric receptors would trigger cytolytic effector programs, a model target:effector system based on CD4 recognition of the HIV envelope gp120/gp41 complex was created. HeLa cells were infected with recombinant vaccinia viruses expressing gp120/gp41 (Chakrabarti et al., Nature 320:535-537 (1986); Earl et al., J. Virol. 64:2448-2451 (1990)) and labeled with ⁵¹Cr. The labeled cells were incubated with cells from a human allospecific (CD8⁺, CD4⁻) cytotoxic T lymphocyte line which had been infected with vaccinia recombinants expressing the CD4:ζ, CD4:η, or CD4:γ chimeras, or the CD4:ζCys11Gly:Asp15Gly double mutant chimera. Fig. 5A-C shows that HeLa cells expressing gp120/41 were specifically lysed by cytotoxic T lymphocytes (CTL) expressing CD4 chimeras. Uninfected HeLa cells were not targeted by CTL armed with CD4:ζ chimeras, and HeLa cells expressing gp120/41 were not recognized by uninfected CTL. To compare the efficacy of the various chimeras, the effector to target ratios were corrected for the fraction of CTL expressing CD4 chimeras, and for the fraction of HeLa cells expressing gp120/41, as measured by flow cytometry. Fig. 5C shows a

- 38 -

cytometric analysis of CD4 expression by the CTL used in the cytolysis experiment shown in Figs. 5A and 5B. Although the mean density of surface CD4:ζ greatly exceeded the mean density of CD4:η, the cytolytic efficiencies of cells expressing either form were similar. Correcting for the fraction of targets expressing gp120, the efficiency of cytolysis mediated by CD4:ζ and CD4:η proteins are comparable to the best target:effector pairs (the mean effector to target ratio for 50% release by T cells expressing CD4:ζ was 1.9 ± 0.99 , n=10. The CD4:γ fusion was less active, as was the CD4:ζ fusion lacking the transmembrane Asp and Cys residues. However in both cases significant cytolysis was observed (Fig. 5B-C).

To control for the possibility that vaccinia infection might promote artefactual recognition by CTL, similar cytolysis experiments were performed with target cells infected with vaccinia recombinants expressing the phosphatidylinositol linked form of CD16 (CD16_{PI}) and labeled with ⁵¹Cr, and with CTL infected with control recombinants expressing either CD16_{PI} or CD16:ζ. Fig. 6A shows that T cells expressing non-CD4 chimeras do not recognize native HeLa cells or HeLa cells expressing gp120/41, and similarly that T cells expressing CD4 chimeras do not recognize HeLa cells expressing other vaccinia-encoded surface proteins. In addition, CTLs expressing non-chimeric CD4 do not significantly lyse HeLa cells expressing gp120/41 (Fig. 6A).

- 39 -

EXAMPLE VII**MHC Class II-Bearing Cells Are Not Targeted by the Chimeras**

CD4 is thought to interact with a nonpolymorphic
5 sequence expressed by MHC class II antigen (Gay et al.,
Nature 328:626-629 (1987); Sleckman et al., Nature
328:351-353 (1987)). Although a specific interaction
between CD4 and class II antigen has never been
10 documented with purified proteins, under certain
conditions adhesion between cells expressing CD4 and
cells expressing class II molecules can be demonstrated
(Doyle et al., Nature 330:256-259 (1987); Clayton et al.,
J. Exp. Med. 172:1243-1253 (1990); Lamarre et al.,
Science 245:743-746 (1989)). Next examined was whether
15 killing could be detected against cells bearing class II.
Fig. 6B shows that there is no specific cytolysis
directed by CD4:ζ against the Raji B cell line, which
expresses abundant class II antigen. Although a modest
(≈5%) cytolysis is observed, a class II-negative mutant
20 of Raji, RJ2.2.5, (Accolla, J. Exp. Med. 157:1053-1058
(1983)) shows a similar susceptibility, as do Raji cells
incubated with uninfected T cells.

EXAMPLE VIII**Sequence Requirements for Induction of Cytolysis by the T
25 Cell Antigen/Fc Receptor Zeta Chain**

Although chimeras between CD4 and ζ can arm
cytotoxic T lymphocytes (CTL) to kill target cells
expressing HIV gp120, an alternative to CD4 was sought in
order to unambiguously compare the properties of zeta
30 chimeras introduced into human T cell lines. Such lines
can express CD4, making it difficult to specifically
define the relationship between the type or degree of
calcium mobilization and the cytotoxic potential of the
different chimeras. To circumvent this, chimeras were

- 40 -

created between ζ and CD16 in which the extracellular domain of CD16 is attached to the transmembrane and intracellular sequences of ζ (Fig. 7A). The gene fusions were introduced into a vaccinia virus expression plasmid bearing the E. coli gpt gene as a selectable marker and inserted into the genome of the vaccinia WR strain by homologous recombination and selection for growth in mycophenolic acid (Falkner and Moss, J. Virol. 62:1849 (1988); Boyle and Coupar, Gene 65:123 (1988)).

T cell lines were infected with the vaccinia recombinants and the relative cytoplasmic free calcium ion concentration was measured following crosslinking of the extracellular domains with antibodies. Both spectrofluorimetric (bulk population) and flow cytometric (single cell) measurements were performed with cells loaded with the dye Indo-1 (Grynkiewicz et al., J. Biol. Chem. 260:3440 (1985); Rabinovitch et al., J. Immunol. 137:952 (1986)). Figure 7B shows an analysis of data collected from cells of the Jurkat human T cell leukemia line infected with vaccinia recombinants expressing CD16: ζ fusion protein. Crosslinking of the chimeras reproducibly increased intracellular calcium, while similar treatment of cells expressing nonchimeric CD16 had little or no effect. When the chimera was expressed in mutant cell lines lacking antigen receptor, either REX33A (Breitmeyer et al., J. Immunol. 138:726 (1987); Sancho et al., J. Biol. Chem. 264:20760 (1989)), or Jurkat mutant JRT3.T3.5 (Weiss et al., J. Immunol. 135:123 (1984)); or a strong response to CD16 antibody crosslinking was seen. Similar data have been collected on the REX20A (Breitmeyer et al., supra, 1987; Blumberg et al., J. Biol. Chem. 265:14036 (1990)) mutant cell line, and a CD3/Ti negative mutant of the Jurkat cell line established in this laboratory. Infection with recombinants expressing CD16: ζ did not restore the

- 41 -

response to anti-CD3 antibody, showing that the fusion protein did not act by rescuing intracellular CD3 complex chains.

To evaluate the ability of the chimeras to
5 redirect cell-mediated immunity, CTLs were infected with vaccinia recombinants expressing CD16 chimeras and used to specifically lyse hybridoma cells expressing membrane-bound anti-CD16 antibodies. This assay is an extension of a hybridoma cytotoxicity assay originally developed to
10 analyze effector mechanisms of cells bearing Fc receptors (Graziano and Fanger, J. Immunol. 138:945, 1987; Graziano and Fanger, J. Immunol. 139:35-36, 1987; Shen et al., Mol. Immunol. 26:959, 1989; Fanger et al., Immunol. Today 10: 92, 1989). Fig. 8B shows that expression of CD16:ζ
15 in cytotoxic T lymphocytes allows the armed CTL to kill 3G8 (anti-CD16; Fleit et al., Proc. Natl. Acad. Sci. USA 79:3275, 1982) hybridoma cells, whereas CTL expressing the phosphatidylinositol-linked form of CD16 are inactive. CTL armed with CD16:ζ also do not kill
20 hybridoma cells expressing an irrelevant antibody.

To identify the minimal ζ sequences necessary for cytolysis, a series of deletion mutants were prepared in which successively more of the ζ intracellular domain was removed from the carboxyl terminus (Fig. 8A). Most of
25 the intracellular domain of zeta could be removed with little consequence for cytolytic potential; the full length chimera CD16:ζ was essentially equal in efficacy to the chimera deleted to residue 65, CD16:ζAsp66* (Fig. 8B). A substantial decrease in cytotoxicity was observed
30 on deletion to ζ residue 59 (chimera CD16:ζGlu60*), and further deletion to residue 50 resulted in slightly less activity. However complete loss of activity was not observed even when the intracellular domain was reduced to a three residue transmembrane anchor (Fig. 8B).

- 42 -

Because ζ is a disulfide linked dimer, one explanation for the retention of cytolytic activity was that endogenous ζ was forming heterodimers with the chimeric ζ deletion, thereby reconstituting activity. To test this idea, ζ residues 11 and 15 were changed from Asp and Cys respectively to Gly (Cys11Gly/Asp15Gly), and immunoprecipitations were carried out as follows. Approximately 2×10^6 CV1 cells were infected for one hour in serum free DME medium with recombinant vaccinia at a multiplicity of infection (moi) of at least ten. Six to eight hours post-infection, the cells were detached from the plates with PBS/1mM EDTA and surface labeled with 0.2 mCi ^{125}I per 2×10^6 cells using lactoperoxidase and H_2O_2 by the method of Clark and Einfeld (*Leukocyte Typing II*, pp 155-167, Springer-Verlag, NY, 1986). The labeled cells were collected by centrifugation and lysed in 1% NP-40, 0.1% SDS, 0.15M NaCl, 0.05M Tris, pH 8.0, 5mM MgCl_2 , 5mM KCl, 0.2M iodoacetamide and 1mM PMSF. Nuclei were removed by centrifugation, and CD16 proteins were immunoprecipitated with antibody 3G8 (Fleit et al., *supra*, 1982; Medarex) and anti-mouse IgG agarose (Cappel, Durham, NC). Samples were electrophoresed through an 8% polyacrylamide/SDS gel under non-reducing conditions or through a 10% gel under reducing conditions. These immunoprecipitations confirmed that the CD16: ζ Cys11Gly/Asp15Gly chimera did not associate in disulfide-linked dimer structures.

The cytolytic activity of the mutant receptors was also tested. The mutated chimera deleted to residue 65 (CD16: ζ Cys11Gly/Asp15Gly/Asp66*) was, depending on the conditions of assay, two to eight fold less active in the cytotoxicity assay than the comparable unmutated chimera (CD16: ζ Asp66*), which was usually within a factor of two of, or indistinguishable in activity from, CD16: ζ (Fig. 9B). The reduction in activity of the mutant chimeras is

- 43 -

comparable to the reduction seen with CD4 chimeras of similar structure (see above) and is most likely attributable to the lower efficiency of ζ monomers compared to dimers. In contrast, the Asp⁻, Cys⁻ mutated chimera deleted to residue 59 had no cytolytic activity (Fig. 9B), supporting the hypothesis that association with other chains mediated by the transmembrane Cys and/or Asp residues was responsible for the weak persistence of cytolytic activity in deletions more amino terminal than residue 65.

Flow cytometric studies showed that the deletion mutants lacking transmembrane Asp and Cys residues could still promote an increase in free intracellular calcium ion in response to antibody crosslinking in a TCR⁻ mutant Jurkat cell line (Fig. 9D). Similar results were obtained for chimeras expressed in the parental Jurkat line. In the case of CD16: ζ (Cys11Gly/Asp15Gly/Glu60*, these data demonstrate that the ability to mediate calcium responsiveness can be mutationally separated from the ability to support cytolysis.

To definitively eliminate the possible contribution of ζ transmembrane residues, the transmembrane and first 17 cytoplasmic residues of ζ were replaced by sequences encoding the membrane spanning and first 14 or first 17 cytoplasmic residues of the CD5 or CD7 antigens, respectively (Fig. 9A). The resulting tripartite fusion proteins CD16:5: ζ (48-65) and CD16:7: ζ (48-65) did not form disulfide-linked dimers as do the simpler CD16: ζ chimeras, because they lacked the cysteine residue in the ζ transmembrane domain. Both tripartite chimeras were able to mobilize calcium in Jurkat and TCR negative cell lines (Fig. 9D) and to mount a cytolytic response in CTL (Fig. 9C and data not shown). However truncation of the ζ portion to residue 59 in chimera CD16:7: ζ (48-59) abrogates the ability of

- 44 -

tripartite fusion to direct calcium responsiveness in TCR positive or negative Jurkat cells or cytolysis in mature CTL (Fig. 9C and 9D and data not shown).

To examine the contributions of individual
5 residues within the 18-residue motif, we prepared a number of mutant variants by site-directed mutagenesis, and evaluated their ability to mediate receptor-directed killing under conditions of low (Figs. 10A and 10D) or high (Figs. 10B and 10E) expression of chimeric receptor.
10 Fig. 10A-F shows that while a number of relatively conservative substitutions (i.e., replacing acidic residues with their cognate amides, or tyrosine with phenylalanine) which spanned residues 59 to 63 yielded moderate compromise of cytolytic efficacy, in general the
15 variants retained the ability to mobilize calcium. However collectively these residues comprise an important submotif inasmuch as their deletion eliminates cytolytic activity. Conversion of Tyr 62 to either Phe or Ser eliminated both the cytotoxic and calcium responses. At
20 the amino terminus of the 18 residue segment, replacement of Tyr 51 with Phe abolished both calcium mobilization and cytolytic activity, while substitution of Leu with Ser at position 50 eliminated the calcium response while only partially impairing cytolysis. Without being bound
25 to a particular hypothesis, it is suspected that the inability of the Leu50Ser mutant to mobilize calcium in short term flow cytometric assays does not fully reflect its ability to mediate a substantial increase in free intracellular calcium ion over the longer time span of
30 the cytolysis assay. However, calcium-insensitive cytolytic activity has been reported for some cytolytic T cell lines, and the possibility that a similar phenomenon underlies the results described herein has not been ruled out. Replacement of Asn48 with Ser partially impaired

- 45 -

cytotoxicity in some experiments while having little effect in others.

To investigate the potential role of redundant sequence elements, the intracellular domain of ζ was
5 divided into three segments, spanning residues 33 to 65, 71 to 104, and 104 to 138. Each of these segments was attached to a CD16:CD7 chimera by means of a MluI site introduced just distal to the basic membrane anchoring sequences of the intracellular domain of CD7 (see below;
10 Fig. 11A). Comparison of the cytolytic efficacy of the three elements showed they were essentially equipotent (Fig. 11B). Sequence comparison (Fig. 11A) shows that the second motif bears eleven residues between tyrosines, whereas the first and third motifs bear ten.

15 Although a precise accounting of the process of T cell activation has not been made, it is clear that aggregation of the antigen receptor, or of receptor chimeras which bear ζ intracellular sequences, triggers calcium mobilization, cytokine and granule release, and
20 the appearance of cell surface markers of activation. The active site of ζ , a short linear peptide sequence probably too small to have inherent enzymatic activity, likely interacts with one or at most a few proteins to mediate cellular activation. It is also clear that
25 mobilization of free calcium is not by itself sufficient for cellular activation, as the ability to mediate cytolysis can be mutationally separated from the ability to mediate calcium accumulation.

As shown herein, addition of 18 residues from the
30 intracellular domain of ζ to the transmembrane and intracellular domain of two unrelated proteins allows the resulting chimeras to redirect cytolytic activity against target cells which bind to the extracellular portion of the fusion proteins. Although chimeras bearing the 18
35 residue motif are approximately eight-fold less active

- 46 -

than chimeras based on full length ζ , the reduced activity can be attributed to the loss of transmembrane interactions which normally allow wild-type ζ to form disulfide linked dimers. That is, ζ deletion constructs
5 which have the same carboxyl terminus as the motif and lack transmembrane Cys and Asp residues typically show slightly less activity than chimeras bearing only the 18 residue motif.

The cytolytic competency element on which we have
10 focused has two tyrosines and no serines or threonines, restricting the possible contributions of phosphorylation to activity. Mutation of either tyrosine destroys activity, however, and although preliminary experiments do not point to a substantial tyrosine phosphorylation
15 following crosslinking of chimeric surface antigens bearing the 18 residue motif, the possible participation of such phosphorylation at a low level cannot be excluded. In addition to the effects noted at the two tyrosine residues, a number of amino acid replacements at
20 the amino and carboxyl terminus of the motif weaken activity under conditions of low receptor density.

Sequences similar to the ζ active motif can be found in the cytoplasmic domains of several other transmembrane proteins, including the CD3 δ and γ
25 molecules, the surface IgM associated proteins mb1 and B29, and the β and γ chains of the high affinity IgE receptor, Fc ϵ RI (Reth, Nature 338:383, 1989). Although the function of these sequences is uncertain, if efficiently expressed, each may be capable of autonomous
30 T cell activation, and such activity may explain the residual TCR responsiveness seen in a zeta-negative mutant cell line (Sussman et al., Cell 52:85, 1988).

ζ itself bears three such sequences, approximately equally spaced, and a rough trisection of the
35 intracellular domain shows that each is capable of

- 47 -

initiating a cytolytic response. η , a splice isoform of ζ (Jin et al., supra, 1990; Clayton et al., Proc. Natl. Acad. Sci. USA 88:5202, 1991), lacks the carboxyl half of the third motif. Because removal of the carboxyl half of the first motif abolishes activity, it appears likely that the majority of the biological effectiveness of η can be attributed to the first two motifs. Although by different measures η is equally as active as ζ in promoting antigen-mediated cytokine release (Bauer et al., Proc. Natl. Acad. Sci. USA 88:3842, 1991) or redirected cytotoxicity (see above), η is not phosphorylated in response to receptor stimulation (Bauer et al., supra, 1991). Thus either the presence of all three motifs is required for phosphorylation, or the third motif represents a favored substrate for an unidentified tyrosine kinase.

EXAMPLE IX

Cytolytic Signal Transduction by Human Fc Receptor

To evaluate the actions of different human Fc receptor subtypes, chimeric molecules were created in which the extracellular domain of the human CD4, CD5 or CD16 antigens were joined to the transmembrane and intracellular domains of the FcRII γ A, B1, B2, and C subtypes (nomenclature of Ravetch and Kinet, Ann. Rev. Immunol. 9:457, 1991). Specifically, cDNA sequences corresponding to the transmembrane and cytoplasmic domains of the previously described FcRIIA, B1, and B2 isoforms were amplified from the preexisting clone PC23 or from a human tonsil cDNA library (constructed by standard techniques) using the following synthetic oligonucleotides primers:

CCC GGA TCC CAG CAT GGG CAG CTC TT (SEQ ID NO: 18; FcRII A forward);

- 48 -

CGC GGG GCG GCC GCT TTA GTT ATT ACT GTT GAC ATG
GTC GTT (SEQ ID NO: 19; FcRII A reverse);

GCG GGG GGA TCC CAC TGT CCA AGC TCC CAG CTC TTC
ACC G (SEQ ID NO: 20; FcRII B1 and FcRII B2 forward); and

5 GCG GGG GCG GCC GCC TAA ATA CGG TTC TGG TC (SEQ ID
NO: 21; FcRII B1 and FcRII B2 reverse).

These primers contained cleavage sites for the enzymes
BamHI and NotI, respectively, indented 6 residues from
the 5' end. The NotI site was immediately followed by an
10 antisense stop codon, either CTA or TTA. All primers
contained 18 or more residues complementary to the 5' and
3' ends of the desired fragments. The cDNA fragment
corresponding to the FcRII γ C cytoplasmic domain, which
differs from the IIA isoform in only one amino acid
15 residue (L for P at residue 268) was generated by site
directed mutagenesis by overlap PCR using primers of
sequence:

TCA GAA AGA GAC AAC CTG AAG AAA CCA ACA A (SEQ ID
NO:22) and

20 TTG TTG GTT TCT TCA GGT TGT GTC TTT CTG A (SEQ ID
NO: 23).

The PCR fragments were inserted into vaccinia virus
expression vectors which contained the CD16 or CD4
extracellular domains respectively and subsequently
25 inserted into wild type vaccinia by recombination at the
thymidine kinase locus, using selection for cointegration
of E coli gpt to facilitate identification of the desired
recombinants. The identities of all isoforms (shown in
Fig. 12) were confirmed by dideoxy sequencing.

30 Production of the chimeric receptor proteins was
further confirmed by immunoprecipitation studies.
Approximately 10^7 JRT3.T3.5 cells were infected for one
hour in serum free IMDM medium with recombinant vaccinia
at a multiplicity of infection of at least ten. Twelve
35 hours post-infection, the cells were harvested and

- 49 -

surface labeled with 0.5mCi ^{125}I per 10^7 cells using the lactoperoxidase/glucose oxidase method (Clark and Einfeld, supra). The labeled cells were collected by centrifugation and lysed 1% NP-40, 0.1mM MgCl_2 , 5mM KCl, 5 0.2M iodoacetamide and 1mM PMSF. Nuclei were removed by centrifugation, and CD16 fusion proteins immunoprecipitated with antibody 4G8 and anti-mouse IgG agarose. Samples were electrophoresed under reducing conditions. All immunoprecipitated chimeric receptor 10 molecules were of the expected molecular masses.

To test the ability of the chimeric receptors to mediate an increase in cytoplasmic free calcium ion, the recombinant viruses were used to infect the TCR $^-$ mutant Jurkat cell line JRT3.T3.5 (as described herein) and 15 cytoplasmic free calcium was measured in the cells (as described herein) following crosslinking of the receptor extracellular domains with monoclonal antibody 3G8 or Leu-3A (as described herein). These experiments revealed that the intracellular domains of FcR γ II A and C were 20 capable of mediating an increase in cytoplasmic free calcium ion after crosslinking of the extracellular domains, whereas the intracellular domains of FcR γ II B1 and B2 were inactive under comparable conditions (Fig. 13 A and 13B). The CD4, CD5 and CD16 hybrids of FcR γ II A 25 shared essentially equal capacity to promote the calcium response (Fig. 13A-B). Other cell lines, from both monocytic and lymphocytic lineages, were capable of responding to the signal initiated by crosslinking of the extracellular domains.

30 To explore the involvement of the different FcR γ II intracellular domains in cytotoxicity, human cytotoxic T lymphocytes (CTL) were infected with vaccinia recombinants expressing CD16:FcR γ II A, B1, B2 and C chimeras. The infected cells were then cocultured with 35 ^{51}Cr -loaded hybridoma cells (i.e., 3G8 10-2 cells) which

- 50 -

expressed cell surface antibody to CD16. In this assay CTLs bearing the CD16 chimera killed the hybridoma target cells (allowing release of free ^{51}Cr) if the CD16 extracellular domain of the chimera has been joined to an
5 intracellular segment capable of activating the lymphocyte effector program; this cytolysis assay is described in detail below. Fig. 14A shows that CTL armed with CD16:FcRyIIA and C, but not FcRyII B1 or B2, are capable of lysing target cells expressing cell surface
10 anti-CD16 antibody.

To eliminate the possibility that the specific cytolysis was in some way attributable to interaction with the CD16 moiety, cytolysis experiments were conducted in which the FcRyII intracellular domains were
15 attached to a CD4 extracellular domain. In this case the target cells were HeLa cells expressing HIV envelope gp120/41 proteins (specifically, HeLa cells infected with the vaccinia vector vPE16 (available from the National Institute of Allergy and Infections Disease AIDS
20 Depository, Bethesda, MD). As in the CD16 system, target cells expressing HIV envelope were susceptible to lysis by T cells expressing the CD4:FcRyII A chimera, but not FcRyII B1 or B2 (Fig. 14B).

The intracellular domains of FcRyII A and C share
25 no appreciable sequence homology with any other protein, including the members of the extended FcRy/TCR ζ family. To define the sequence elements responsible for induction of cytolysis, 5' and 3' deletions of the intracellular domain coding sequences (described below and shown in
30 Fig. 15A) were prepared and were evaluated for efficacy in calcium mobilization and cytolysis assays (as described herein). In the experiments in which the amino terminal portion of the intracellular domain was removed, the transmembrane domain of FcRyII was replaced with the
35 transmembrane domain of the unrelated CD7 antigen to

- 51 -

eliminate the possible contribution of interactions mediated by the membrane-spanning domain.

Figs. 15B and 15C show that removal of the 14 carboxyl-terminal residues, including tyrosine 298, resulted in a complete loss of cytolytic capacity and a substantial reduction in calcium mobilization potential. Further deletion to just before tyrosine 282 gave an identical phenotype (Figs. 15B and 15C). Deletion from the N-terminus of the intracellular domain to residue 268 had no substantial effect on either calcium profile or cytolytic potency, whereas deletion to residue 275 markedly impaired free calcium release but had little effect on cytolysis (Figs. 15D and 15E). Further deletion, to residue 282, gave FCγRII tails which lacked the ability to either mobilize calcium or trigger cytolysis (Figs. 15D and 15E). The 'active element' defined by these crude measures is relatively large (36 amino acids) and contains two tyrosines separated by 16 residues.

20

EXAMPLE X

Targeted Cytolysis by Lymphocytes Bearing Chimeric CD4 Receptors Which Do Not Support Infection

As discussed above, effector molecules may be engineered which redirect the cytolytic activity of CTLs in an MHC-independent manner. For example, a chimera composed of the extracellular domain of CD4 fused to the ζ chain in a human CTL clone, WH3, specifically kills target cells displaying the surface envelope glycoprotein of HIV-1, gp120. Since the extracellular domain of the CD4 molecule confers susceptibility to HIV infection, however, the armed CTLs may become targets for the virus, resulting in a decrease in their potency (Dalglish et al., Nature 312:767 (1984); Klatzmann et al., Nature 312:767 (1984)). To prevent such an outcome, chimeric

- 52 -

effector molecules were designed based on CD4 which are effective in specifically targeting HIV-infected cells for cell-mediated killing but which do not confer susceptibility to infection by HIV.

5 A tripartite fusion protein was created by genetic apposition of the extracellular domain of CD4 (Fig. 23) to the hinge, second, and third constant domains of human IgG1 heavy chain (Zettlmeissl et al. DNA Cell Biol. 9:347 (1990)) (Fig. 25), which were joined in this case to a
10 portion of the first transmembrane exon of human membrane-bound IgG1, followed by a portion of the human CD7 antigen consisting of the sequences between the sole Ig-like domain and the stop transfer sequence following the transmembrane domain (Aruffo and Seed, EMBO J. 6:3313
15 (1987)) (Fig. 26). The primary amino acid sequence of the extracellular moiety of the CD7 segment consisted of a proline-rich region suggestive of a stalk-like structure which projects the Ig-like domain away from the cell surface (Aruffo and Seed EMBO J. 6:3313 (1987))
20 (Fig. 26). Recombinant vaccinia viruses were prepared to express this and related chimeras as described herein. In particular, recombinant vaccinia viruses were generated by homologous recombination in CV-1 cells. At least two rounds of plaque visualization with OKT4 or
25 Leu3a followed by plaque purification was performed for each stock prior to preparation of high titer stocks in CV-1 cells.

The tripartite chimera (CD4(D1-D4):Ig:CD7) (Fig. 20, molecule "A") showed efficient cell surface
30 expression and was tested for the ability to act as an HIV receptor in a vaccinia-based syncytia formation assay (Lifson et al., Nature 323:725 (1986)); Ashorn et al., J. Virol. 64:2149 (1990)). HeLa cells infected with a recombinant vaccinia virus (vPE16) encoding the envelope
35 glycoprotein of HIV-1 (Earl et al., J. Virol. 64:2448

- 53 -

(1990)) were co-cultured with HeLa cells infected either with CD4, CD4:ζ, or CD4(D1-D4):Ig:CD7. Six cm dishes of HeLa cells (ATCC, Rockville, MD) at 50% confluence were infected in serum-free medium for 1 hour at an
5 approximate multiplicity of infection (MOI) of 10. The cells were incubated for an additional 5-6 hours in complete medium and then detached with phosphate buffered saline (PBS) containing 1mM EDTA. Cells expressing envelope and CD4 chimera were mixed at a 1:1 ratio, and
10 replated in 6 cm dishes with complete medium. Syncytia were scored at 6-8 hours post-cocultivation and photographed.

Co-cultures of CD4 and vPE16 led to formation of readily detectable multinucleated giant cells. Also, a
15 chimera consisting of the extracellular domain of CD4 fused to the ζ chain of the TCR (Fig. 27) (CD4:ζ) was able to mediate syncytia formation, whereas cells expressing CD4(D1-D4):Ig:CD7 gave no sign of cell fusion. We also tested a construct expressing only the first and
20 second domains of CD4 (Fig. 24), CD4(D1,D2):Ig:CD7 (Fig. 20, molecule "B"), since in another context the amino terminal two domains of the CD4 have been shown to be necessary for infectivity by HIV (Landau et al., Nature 334:159 (1988)). This molecule proved insusceptible to
25 HIV-induced syncytia formation as well. Binding studies with soluble ¹²⁵I-labelled gp120 established that both CD4(D1-D4):Ig:CD7 and CD4(D1,D2):Ig:CD7 had uncompromised affinity for gp120.

We next determined whether chimeric molecules
30 which resisted syncytium formation would be able to redirect cell killing if endowed with a trigger moiety as described herein. We fused the intracellular domain of ζ (Fig. 27) to the 3' end of CD4(D1-D4):Ig:CD7 and CD4(D1,D2):Ig:CD7 and prepared the corresponding
35 recombinant vaccinia viruses. These constructs, CD4(D1-

- 54 -

D4):Ig:CD7:ζ and CD4(D1,D2):Ig:CD7:ζ (Fig. 20, molecules "C" and "D"), were expressed in the human CTL clone WH3 and tested for their ability to target and kill HeLa cells expressing the surface envelope glycoprotein of HIV (using the methods described herein). Fig. 21 shows that the intracellular domain of ζ fused to either CD4(D1-D4):Ig:CD7 or CD4(D1,D2):Ig:CD7 can confer killing ability; constructs lacking the ζ chain were not able to mediate this activity. CD4:ζ, a positive control, mediated a slightly more effective cytotoxicity, and CD4(D1,D2):Ig:CD7:ζ a somewhat less effective cytotoxicity than CD4(D1-D4):Ig:CD7:ζ (Fig. 21). However, it is clear that both CD4(D1-D4):Ig:CD7:ζ and CD4(D1,D2):Ig:CD7:ζ chimeras have the capacity to mediate specific killing of cells expressing HIV envelope proteins on their surface. The tetrapartite chimeras were consistently incapable of mediating syncytium formation in the vaccinia-based assay. We have also demonstrated that a single ζ motif of the sort shown in Fig. 11A is sufficient to confer cytolytic activity to a CD4(D1-D4) chimera.

Radioimmunoprecipitation experiments established that the fusion molecules were predominantly if not entirely dimers. In these experiments, protein-A agarose beads were used to immunoprecipitate the solubilized extract of metabolically labelled HeLa cells infected with recombinant vaccinia expressing CD4(D1-D4):Ig:CD7:ζ and CD4(D1,D2):Ig:CD7:ζ chimeras. The immunoprecipitated material was fractionated by polyacrylamide gel electrophoresis under reducing and nonreducing conditions. In particular, approximately 5×10^6 HeLa-S3 cells were infected as described above for vPE16 with the appropriate vaccinia virus stock. Cells were metabolically labelled with 200 μCi/ml of Tran³⁵S-Label (ICN Radiochemicals, Irvine, CA) for 6-8 hours in

- 55 -

cysteine and methionine-deficient medium and detached with PBS containing 1mM EDTA. Cells were subsequently pelleted and lysed in 150mM NaCl, 50mM Tris pH 7.5, 5mM EDTA, 0.5% NP-40, 0.1% SDS, 5mM EDTA, 1mM PMSF.

5 Following the removal of the nuclei by centrifugation, one fifth of each cell extract was adsorbed onto washed protein A-conjugated agarose beads for 2 hours at 4°C. The beads were subsequently washed with PBS containing 1% NP-40 and eluted in sample buffer containing SDS in the
10 presence or absence of mercaptoethanol. The results of these experiments demonstrated that the majority of the immunoprecipitated CD4(D1-D4):Ig:CD7:ζ and CD4(D1,D2):Ig:CD7:ζ chimeras migrated as dimers of the expected molecular mass under nonreducing conditions.

15 To directly evaluate the ability of cells expressing the CD4 fusion molecules to support HIV infection, we performed long term infectivity studies on transfectants expressing CD4(D1-D4):Ig:CD7 and CD4(D1,D2):Ig:CD7. Stable transfectants of CD4(D1-D4):Ig:CD7 and CD4(D1,D2):Ig:CD7 and CD4 were prepared in
20 a subline of 293 cells, a readily transfectable cell line of human embryonic kidney origin. The chimeric molecules were subcloned in bidirectional vectors in which the hygromycin B gene was driven by the herpes simplex virus
25 thymidine kinase promoter. A 60-70% confluent 10 cm dish of cells was transfected with 10 μg of this plasmid DNA by calcium phosphate coprecipitation. Prior to transfection, the plasmids were linearized at the unique Sfi I site, and the ends made flush with T4 DNA
30 polymerase. At 24 hours post-transfection, the cells were split fourfold and at 48 hours post-transfection the cells were put under selection with hygromycin B (Sigma, St. Louis, Mo) at 400 μg/ml. Every 3-4 days, cells were supplied with fresh medium containing hygromycin.

- 56 -

Resistant colonies were picked, expanded, and their expression assessed by indirect immunofluorescence using fluorescein-conjugated anti-human IgG Fc (Organon Teknika, West Chester, PA) or Q4120, an antibody reactive with human CD4 (Sigma) followed by flow cytometry (Coulter, Hialeah, FL). Two independent clones from each construct with levels of cell surface CD4 comparable to that shown by the other cell lines were selected for analysis. Fig. 22 shows that, following exposure to HIV, p24 was detected in the CD4 stable transfectant cultures as early as 3 days post-infection. The presence of multinucleated giant cells and characteristic ballooning was evident as early as 5 days post-infection in these cultures. No significant p24 levels or evidence of multinucleated giant cells was detectable in the untransfected parental cell line or in either of two independently derived isolates of CD4(D1-D4):Ig:CD7 and CD4(D1,D2):Ig:CD7 transfectants after 32 days in culture (Fig. 22).

Upon completion of the infectivity studies, cells were analyzed for cell surface CD4 expression. CD4 surface epitope density was significantly reduced in infected cultures expressing CD4, consistent with viral down-modulation, but was unaffected in cultures expressing CD4(D1-D4):Ig:CD7 and CD4(D1,D2):Ig:CD7. These experiments establish that it is possible to create chimeric molecules bearing the apical two domains of CD4 which, when fused to T cell receptor ζ chain, have the capacity to target and kill HIV-infected cells, but which do not support CD4-mediated HIV infection.

Additional experiments suggest that it is the physical distance between the extracellular domain of the CD4 molecule and the lipid bilayer that confers the ability to resist HIV infection. In a first experiment, we constructed a chimeric molecule bearing a deletion of

- 57 -

the CD7 stalk and transmembrane domain; this deletion removed the proline rich region of the CD7 transmembrane portion. When this domain was fused to the extracellular domain of CD4, it maintained its ability to efficiently anchor the extracellular domain of the CD4 molecule, as measured by cell surface expression of the CD4 molecule (as described herein). However, the potential to resist syncytium formation induced by the HIV envelope glycoprotein was lost. Thus, deletion of the proline-rich region of the CD7 molecule, a region likely to form an α -helical coil structure, effectively reduced the distance between the extracellular domain of CD4 and the lipid bilayer and abrogated the ability of the chimera to resist syncytium formation.

In a second experiment, we demonstrated that the ability to resist HIV-induced syncytium formation may be conferred upon a CD4/CD5 chimera which had previously been documented to serve as a transmembrane anchor for a CD4 extracellular domain but which was unable to resist HIV-induced syncytium formation. In this experiment, the hinge, CH2, and CH3 domains of the human IgG1 heavy chain were inserted into the CD4/CD5 molecule; the resulting chimera resisted syncytium formation, again suggesting that the distance afforded by the immunoglobulin domains is sufficient to confer resistance to HIV-induced syncytium formation.

In a third experiment, a CD4 domain was extended varying distances from the cell membrane using synthetic alpha helices of varying length. In particular, synthetic oligonucleotides representing repeated alpha helical motifs of lysine and glutamic acid residues flanked by two alanine residues were designed (see Fig. 28 for the primary nucleic acid and amino acid sequences). In previous studies, such amino acid sequences were found to occur with high frequency in

- 58 -

alpha helices, suggesting that such repeated motifs would adopt an alpha helical conformation and that placement of such alpha helices between the transmembrane domain and extracellular domains of CD4 would project CD4 away from
5 the cell membrane. By varying the length of the alpha helical segment, a calculation of the projection distance necessary to resist HIV entry was determined based on known values for alpha helical rise and turn. These results are presented in Table 1.

- 59 -

TABLE 1

	Syncytia Formation	Thy-1 Expression
A. CD4+H+CH2+CH3+CD7cm+stk	-	-
B. CD4(D1,D2)+H+CH2+CH3+CD7cm+stk	-	-
C. CD4+CD7cm+stk	+/- (a)	+
D. CD4+CD7cm (long version)	+	+
E. CD4+CD7cm (short version)	+	+
F. CD4+CD5cm	+	+
G. CD4+CH2+CH3+CD5cm	-	-
H. CD4+CH3+CD5cm	-	ND
I. CD4+CD34cm	+	+
J. CD4+synthetic alpha helix (24 angstroms)+CD34cm	ND	+
K. CD4+synthetic alpha helix (48 angstroms)+CD34cm	ND	+/- (a)
L. CD4+synthetic alpha helix (72 angstroms)+CD34cm	ND	-

a Substantial reduction in the number of syncytia or thy-1-expressing cells.

- 60 -

In this Table, "CD4" represents CD4(D1-D4) unless otherwise noted; "H", "CH2", and "CH3" represent the hinge, CH2, and CH3 regions of the human IgG1 heavy chain, respectively; "CD7tm and stk" represents the CD7 transmembrane and stalk regions; "CD7tm (long version)" and "CD7tm (short version)" represent respectively the CD7 transmembrane region and the CD7 transmembrane region deleted for the proline-rich domain (as discussed above); "CD5tm" represents the CD5 transmembrane region; and "CD34tm" represents the CD34 transmembrane region. In entries J-L, the length of the alpha helical region is denoted in angstroms; these values are based on the fact that there are 3.6 residues per turn of an alpha helix, corresponding to 5.4 A (or 1.5A per residue). Accordingly, a 16 residue alpha helix would project the extracellular domain of CD4 about 24 angstroms. The 48 and 72 angstrom alpha helices were constructed by sequential concatemerization of the BstY1 fragment into the fragment's unique BamH1 site (see Fig. 28), followed by selection of clones with the proper orientation.

Syncytia formation was scored in co-cultivation assays with HeLa cells expressing the HIV-1 envelope glycoprotein from the vaccinia virus vPE-16 construct (see above).

Thy-1 expression was measured as follows. A live retrovirus vector was constructed based on the hxb.2 clone of HIV-1. In this vector, the non-essential nef gene was replaced with the coding sequence of rat thy-1, an efficiently expressed cell surface molecule that is anchored to the membrane by a phosphatidyl-inositol linkage. The virus derived from this molecular clone, designated hxb/thy-1, was infectious as evidenced by its cytopathological effects and by the production of p24 in culture supernatants of infected C8166 cells (a human CD4⁺ leukemic T-cell line). In addition, upon exposure

- 61 -

to hxb/thy-1, HeLa cells transiently transfected with CD4 showed signs of thy-1 expression in as early as 18 hours post-infection, as would be expected of a message regulated in a nef-like manner. Messages encoded by the nef gene normally fall into a class of viral regulatory proteins which are multiply spliced and lack the rev-response element. These messages can accumulate constitutively in the cytoplasm as early viral gene products. The thy-1 messages were expected to be similarly regulated, that is, to occur early in the life cycle of the virus. In short, this system facilitated the assay of HIV entry, with thy-1 expression employed as a surrogate for viral entry. Various CD4-based chimeras were transiently transfected into HeLa cells using standard DEAE-dextran methods. The transfected cells were exposed to hxb/thy-1 virus at 48 hours post-transfection and scored for thy-1 expression at 24-48 hours post-infection. In the results shown in Table 1, thy-1 expression was measured at 24 hours post-infection using a commercially available Thy-1 monoclonal antibody (Accurate).

From the data presented in Table 1, we concluded that the extracellular domains of CD4 should optimally be projected away from the cell membrane by at least 48 angstroms, and preferably by at least 72 angstroms in order to resist HIV-1 infection.

Using a strategy similar to the general strategy described herein, chimeras based on anti-HIV envelope antibodies may be constructed which target HIV-infected cells. Examples of such antibodies are described in Gorny et al., Proc. Natl. Acad. Sci. USA 86:1624 (1989) and Marasco et al., J. Clin. Invest. 90:1467 (1992).

- 62 -

EXAMPLE XI**Additional T Cell Receptor and B Cell Receptor Trigger Proteins**

Other intracellular and transmembrane signal
5 transducing domains according to the invention may be
derived from the T cell receptor proteins, CD3 delta and
T3 gamma, and the B cell receptor proteins, mb1 and B29.
The amino acid sequences of these proteins are shown in
Fig. 16 (CD3 delta; SEQ ID NO: 24), Fig. 17 (T3 gamma;
10 SEQ ID NO: 25), Fig. 18 (mb1; SEQ ID NO: 26) and Fig. 19
(B29; SEQ ID NO: 27). The portions of the sequences
sufficient for cytolytic signal transduction (and
therefore preferably included in a chimeric receptor of
the invention) are shown in brackets. Chimeric receptors
15 which include these protein domains are constructed and
used in the therapeutic methods of the invention
generally as described above.

EXAMPLE XII**Experimental Methods****20 Vaccinia Infection and Radioimmunoprecipitation**

Approximately 5×10^6 CV1 cells were infected for
one hour in serum free DME medium with recombinant
vaccinia at a multiplicity of infection (moi) of at least
ten (titer measured on CV1 cells). The cells were placed
25 in fresh medium after infection and labelled
metabolically with $200\mu\text{Ci/ml}$ ^{35}S -methionine plus cysteine
(Tran ^{35}S -label, ICN; Costo Mesa, CA) in methionine and
cysteine free DMEM (Gibco; Grand Island, NY) for six
hours. The labelled cells were detached with PBS
30 containing 1mM EDTA, collected by centrifugation, and
lysed in 1% NP-40, 0.1% SDS, 0.15 M NaCl, 0.05M Tris pH
8.0, 5mM EDTA, and 1mM PMSF. Nuclei were removed by
centrifugation, and CD4 proteins immunoprecipitated with
OKT4 antibody and anti-mouse IgG agarose (Cappel, Durham,

- 63 -

NC). Samples were electrophoresed through 8% polyacrylamide/SDS gels under non-reducing (NR) and reducing (R) conditions. Gels containing ^{35}S -labelled samples were impregnated with En³Hance (New England Nuclear, Boston, MA) prior to autoradiography. Facilitated expression of the transmembrane form of CD16, CD16_{TM}, was measured by comparing its expression in CV1 cells singly infected with CD16_{TM} with expression in cells coinfecting with viruses encoding CD16_{TM} and ζ or γ chimeras. After infection and incubation for six hours or more, cells were detached from plates with PBS, 1mM EDTA and the expression of CD16_{TM} or the chimeras was measured by indirect immunofluorescence and flow cytometry.

15 Calcium Flux Assay

Jurkat subline E6 (Weiss et al., J. Immunol. 133:123-128 (1984)) cells were infected with recombinant vaccinia viruses for one hour in serum free IMDM at an moi of 10 and incubated for three to nine hours in IMDM, 10% FBS. Cells were collected by centrifugation and resuspended at 3×10^6 cells/ml in complete medium containing 1mM Indo-1 acetomethoxyester (Grynkiewicz et al., J. Biol. Chem. 260:3340-3450 (1985)) (Molecular Probes) and incubated at 37°C for 45 minutes. The Indo-1 loaded cells were pelleted and resuspended at 1×10^6 /ml in serum free IMDM and stored at room temperature in the dark. Cells were analyzed for free calcium ion by simultaneous measurement of the violet and blue fluorescence emission by flow cytometry (Rabinovitch et al., J. Immunol. 137:952-961 (1986)). To initiate calcium flux, either phycoerythrin (PE)-conjugated Leu-3A (anti-CD4) (Becton Dickinson, Lincoln Park, NJ) at 1 $\mu\text{g}/\text{ml}$ was added to the cell suspension followed by 10 $\mu\text{g}/\text{ml}$ of unconjugated goat anti-mouse IgG at time 0 or 35 unconjugated 3G8 (anti-CD16) monoclonal antibody was

- 64 -

added to the cell suspension at 1 $\mu\text{g/ml}$ followed by 10 $\mu\text{g/ml}$ of PE-conjugated Fab_2' goat anti-mouse IgG at time 0. Histograms of the violet/blue emission ratio were collected from the PE positive (infected) cell population, which typically represented 40-80% of all cells. The T cell antigen receptor response in uninfected cells was triggered by antibody OKT3, without crosslinking. For experiments involving CD16 chimeric receptors, samples showing baseline drift toward lower intracellular calcium (without antibody) were excluded from the analysis. Histogram data were subsequently analyzed by conversion of the binary data to ASCII using Write Hand Man (Cooper City, FL) software, followed by analysis with a collection of FORTRAN programs. The violet/blue emission ratio prior to the addition of the second antibody reagents was used to establish the normalized initial ratio, set equal to unity, and the resting threshold ratio, set so that 10% of the resting population would exceed threshold.

20 Cytolysis Assay

Human T cell line WH3, a $\text{CD8}^+ \text{CD4}^- \text{HLA B44}$ restricted cytolytic line was maintained in IMDM, 10% human serum with 100 U/ml of IL-2 and was periodically stimulated either nonspecifically with irradiated (3000 rad) HLA-unmatched peripheral blood lymphocytes and 1 $\mu\text{g/ml}$ of phytohemagglutinin, or specifically, with irradiated B44-bearing mononuclear cells. After one day of nonspecific stimulation, the PHA was diluted to 0.5 $\mu\text{g/ml}$ by addition of fresh medium, and after three days the medium was changed. Cells were grown for at least 10 days following stimulation before use in cytotoxicity assays. The cells were infected with recombinant vaccinia at a multiplicity of infection of at least 10 for on hour in serum free medium, followed by incubation

- 65 -

in complete medium for three hours. Cells were harvested by centrifugation and resuspended at a density of 1×10^7 cells/ml. 100 μ l were added to each well of a U-bottom microtiter plate containing 100 μ l/well of complete
5 medium. Cells were diluted in two-fold serial steps. Two wells for each sample did not contain lymphocytes, to allow spontaneous chromium release and total chromium uptake to be measured. The target cells, from HeLa subline S3, were infected in 6.0 or 10.0 cm plates at an
10 approximate moi of 10 for one hour in serum free medium, followed by incubation in complete medium for three hours. They were then detached from the dishes with PBS, 1mM EDTA and counted. An aliquot of 10^6 target cells (HeLa, Raji, or RJ2.2.5 cells for the CD4 chimeric
15 receptor experiments and 3G8 10-2 cells; Shen et al., Mol. Immunol. 26:959 (1989) for the CD16 chimeric receptor experiments) was centrifuged and resuspended in 50 μ l of sterile ^{51}Cr -sodium chromate (1mCi/ml, Dupont Wilmington, DE) for one hour at 37°C with intermittent
20 mixing, then washed three times with PBS. 100 μ l of labelled cells resuspended in medium at 10^5 cells/ml were added to each well. Raji and RJ2.2.5 target cells were labelled in the same manner as HeLa cells. The microtiter plate was spun at 750 x g for 1 minute and
25 incubated for 4 hours at 37°C. At the end of the incubation period, the cells in each well were resuspended by gentle pipetting, a sample removed to determine the total counts incorporated, and the microtiter plate spun at 750 x g for 1 minute. 100 μ l
30 aliquots of supernatant were removed and counted in a gamma ray scintillation counter. The percent killing was corrected for the fraction of infected target cells (usually 50-90%) measured by flow cytometry. For infected effector cells the effector:target ratio was
35 corrected for the percent of cells infected (usually 20-

- 66 -

50% for the CD4 chimeric receptor experiments and >70% for the CD16 chimeric receptor experiments).

In Vitro Mutagenesis of the ζ Sequence

To create point mutations in amino acid residues 11 and or 15 of the ζ sequence, synthetic oligonucleotide primers extending from the BamHI site upstream of the ζ transmembrane domain, and converting native ζ residue 11 from Cys to Gly (C11G) or residue 15 from Asp to Gly (D15G) or both (C11G/D15G) were prepared and used in PCR reactions to generate mutated fragments which were reinserted into the wild type CD4: ζ constructs.

To create ζ deletions, ζ cDNA sequences were amplified by PCR using synthetic oligonucleotide primers designed to create a stop codon (UAG) after residues 50, 59, or 65. The primers contained the cleavage site for the enzyme NotI indented five or six residues from the 5' end, usually in a sequence of the form CGC GGG CGG CCG CTA (SEQ ID NO: 11), where the last three residues correspond to the stop anticodon. The NotI and stop anticodon sequences were followed by 18 or more residues complementary to the desired 3' end of the fragment. The resulting chimeras were designated CD16: ζ Y51*, CD16: ζ E60* and CD16: ζ D66* respectively. The BamHI site upstream of the transmembrane domain and the NotI site were used to generate fragments that were reintroduced into the wild type CD16: ζ construct. Monomeric ζ chimeras were created by liberating the ζ transmembrane and membrane proximal intracellular sequences by BamHI and SacI digestion of the Asp⁻ and Cys⁻ CD4: ζ construct described above and inserting the fragment into the CD16: ζ E60* and CD16: ζ D66* construct respectively.

CD16:7: ζ (48-65) and CD16:7 ζ (48-59) tripartite chimera construction.

To prepare the construct CD16: ζ D66*, the ζ cDNA sequence corresponding to the transmembrane domain and

- 67 -

the 17 following residues of the cytoplasmic domain was replaced by corresponding transmembrane and cytoplasmic domain obtained from the CD5 and CD7 cDNA. The CD5 and CD7 fragments were generated by a PCR reaction using
5 forward oligonucleotides including a BamHI restriction cleavage site and corresponding to the region just upstream of the transmembrane domain of CD5 and CD7 respectively and the following reverse oligonucleotides overlapping the CD5 and CD7 sequences respectively and
10 the ζ sequence which contained the SacI restriction cleavage site.

CD5: ζ : CGC GGG CTC GTT ATA GAG CTG GTT CTG GCG
CTG CTT CTT CTG (SEQ ID NO: 12)

CD7: ζ : CGC GGG GAG CTC GTT ATA GAG CTG GTT TGC
15 CGC CGA ATT CTT ATC CCG (SEQ ID NO: 13).

The CD5 and CD7 PCR products were digested with BamHI and SacI and ligated to BamHI and SacI digested CD16: ζ E60* and replacing the ζ sequence from BamHI to SacI by the CD7 fragment. To make the constructs CD16:CD5 and
20 CD16:CD7, CD5 and CD7 fragments were obtained by PCR using an oligonucleotide containing a NotI restriction cleavage site and encoding a stop codon (UAA) after the residue Gln416 and Ala193 of CD5 and CD7 respectively. The CD5 and CD7 PCR fragment were digested with BamHI and
25 NotI and inserted in the CD16: ζ Asp66* construct.

In Vitro Mutagenesis of the N-terminal Residues within the ζ Cytolytic Signal-Transducing Motif

Synthetic oligonucleotide primers extending from the SacI site inside the ζ motif and converting native
30 residue 48 from Asn to Ser (N48S), residue 50 from Leu to Ser (L50S) and residue 51 from Tyr to Phe (Y51F) were synthesized and used in a PCR reaction to generate fragments that were reintroduced into the wild type CD16:7: ζ (48-65) construct.

- 68 -

In Vitro Mutagenesis of C-terminal Residues within the ζ Cytolytic Signal-Transducing Motif

Synthetic oligonucleotide primers extending from the NotI site 3' to the stop codon and converting native
5 residue 60 from Glu to Gln (E60Q), residue 61 from Glu to Gln (E61Q), residue 62 from Tyr to Phe or Ser (Y62F or Y62S) and residue 63 from Asp to Asn (D63N) were synthesized and used in PCR to generate fragments that were subcloned into the wild type CD16:ζD66* construct
10 from the BamHI site to the NotI site.

CD16:7:ζ(33-65), CD16:7:ζ(71-104), CD16:7:ζ(104-137)

Chimera Constructions

A CD7 transmembrane fragment bearing MluI and NotI sites at the junction between the transmembrane and
15 intracellular domains was obtained by PCR using an oligonucleotide with the following sequence: CGC GGG GCG GCC ACG CGT CCT CGC CAG CAC ACA (SEQ ID NO:14). The resulting PCR fragment was digested with BamHI and NotI and reinserted into the CD16:7:ζ(48-65) construct. ζ
20 fragments encoding residues 33 to 65, 71 to 104, and 104 to 137 were obtained by PCR reaction using pairs of primers containing MluI sites at the 5' end of the forward primers and stop codons followed by NotI sites at the 5' end of the reverse primers. In each case the
25 restriction sites were indented six residues from the 5' terminus of the primer to insure restriction enzyme cleavage.

ζ 33: CGC GGG ACG CGT TTC AGC CGT CCT CGC CAG CAC ACA (SEQ ID NO: 15);

30 ζ 71: CGC GGG ACG CGT GAC CCT GAG ATG GGG GGA AAG (SEQ ID NO: 16); and

ζ 104: CGC GGG ACG CGT ATT GGG ATG AAA GGC GAG CGC (SEQ ID NO: 17).

- 69 -

Construction of FcR γ IIA Deletion Mutants

Carboxyl terminal FCRIIA deletion mutants were constructed by PCR in the same fashion as for the full length constructs, converting the sequences encoding tyrosine at positions 282 and 298 into stop codons (TAA). The N-terminal deletions were generated by amplifying fragments encoding successively less of the intracellular domain by PCR, using oligonucleotides which allowed the resulting fragments to be inserted between MluI and NotI restriction sites into a previously constructed expression plasmid encoding the CD16 extracellular domain fused to the CD7 transmembrane domain, the latter terminating in a MluI site at the junction between the transmembrane and the intracellular domain.

15

OTHER EMBODIMENTS

The examples described above demonstrate that aggregation of ζ , η , or γ chimeras suffices to initiate the cytolytic effector cell response in T cells. The known range of expression of ζ , η , and γ , which includes T lymphocytes, natural killer cells, basophilic granulocytes, macrophages and mast cells, suggests that conserved sequence motifs may interact with a sensory apparatus common to cells of hematopoietic origin and that an important component of host defense in the immune system may be mediated by receptor aggregation events.

The potency of the cytolytic response and the absence of a response to target cells bearing MHC class II receptors demonstrates that chimeras based on ζ , η , or γ form the basis for a genetic intervention for AIDS through adoptive immunotherapy. The broad distribution of endogenous ζ and γ and evidence that Fc receptors associated with γ mediate cytotoxicity in different cells types (Fanger et al., Immunol. Today 10:92-99 (1989)) allows a variety of cells to be considered for this

- 70 -

purpose. For example, neutrophilic granulocytes, which have a very short lifespan ($\approx 4h$) in circulation and are intensely cytolytic, are attractive target cells for expression of the chimeras. Infection of neutrophils with HIV is not likely to result in virus release, and the abundance of these cells (the most prevalent of the leukocytes) should facilitate host defense. Another attractive possibility for host cells are mature T cells, a population presently accessible to retroviral engineering (Rosenberg, S.A. Sci. Am. 262:62-69 (1990)). With the aid of recombinant IL-2, T cell populations can be expanded in culture with relative ease, and the expanded populations typically have a limited lifespan when reinfused (Rosenberg et al., N. Engl. J. Med. 323:570-578 (1990)).

Under the appropriate conditions, HIV recognition by cells expressing CD4 chimeras should also provide mitogenic stimuli, allowing the possibility that the armed cell population could respond dynamically to the viral burden. Although we have focused here on the behavior of the fusion proteins in cytolytic T lymphocytes, expression of the chimeras in helper lymphocytes might provide an HIV-mobilized source of cytokines which could counteract the collapse of the helper cell subset in AIDS. Recent description of several schemes for engineering resistance to infection at steps other than virus penetration (Friedman et al., Nature 335:452-454 (1988); Green et al., Cell 58:215-223 (1989); Malim et al., Cell 58:205-214 (1989); Trono et al., Cell 59:113-120 (1989); Buonocore et al., Nature 345:625-628 (1990)) suggests that cells bearing CD4 chimeras could be designed to thwart virus production by expression of appropriate agents having an intracellular site of action.

- 71 -

The ability to transmit signals to T lymphocytes through autonomous chimeras also provides the ability for the regulation of retrovirally engineered lymphocytes in vivo. Crosslinking stimuli, mediated for example by
5 specific IgM antibodies engineered to remove complement-binding domains, may allow such lymphocytes to increase in number in situ, while treatment with similar specific IgG antibodies (for example recognizing an amino acid variation engineered into the chimeric chain) could
10 selectively deplete the engineered population. Additionally, anti-CD4 IgM antibodies do not require additional crosslinking to mobilize calcium in Jurkat cells expressing CD4:ζ chimeras. The ability to regulate cell populations without recourse to repeated
15 extracorporeal amplification may substantially extend the range and efficacy of current uses proposed for genetically engineered T cells.

While the invention has been described in connection with specific embodiments thereof, it will be
20 understood that it is capable of further modifications and this application is intended to cover variations, uses, or adaptations of the invention and including such departures from the present disclosure as come within the art to which the invention pertains and as may be applied
25 to the essential features hereinbefore set forth as follows in the scope of the appended claims.

- 72 -

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- (i) APPLICANTS: Seed, Brian et al.
- (ii) TITLE OF INVENTION: Targeted Cytolysis of HIV-Infected Cells by Chimeric CD4 Receptor-Bearing Cells
- (iii) NUMBER OF SEQUENCES: 27
- (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: Fish & Richardson
 - (B) STREET: 225 Franklin Street
 - (C) CITY: Boston
 - (D) STATE: MA
 - (E) COUNTRY: USA
 - (F) ZIP: 02110-2804
- (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
 - (B) COMPUTER: IBM PS/2 Model 50Z or 55SX
 - (C) OPERATING SYSTEM: IBM P.C. DOS (Version 3.30)
 - (D) SOFTWARE: Wordperfect (Version 5.0)
- (vi) CURRENT APPLICATION DATA:
 - (A) APPLICATION NUMBER:
 - (B) FILING DATE:
 - (C) CLASSIFICATION:
- (vii) PRIOR APPLICATION DATA:
 - (A) APPLICATION NUMBER: 07/847,566
 - (B) FILING DATE: March 6, 1992
 - (C) CLASSIFICATION:
- (vii) PRIOR APPLICATION DATA:
 - (A) APPLICATION NUMBER: 07/665,961
 - (B) FILING DATE: March 7, 1991
 - (C) CLASSIFICATION:
- (viii) ATTORNEY/AGENT INFORMATION:
 - (A) NAME: Clark, Paul T.
 - (B) REGISTRATION NUMBER: 30,162
 - (C) REFERENCE/DOCKET NUMBER: 00786/212001
- (ix) TELECOMMUNICATION INFORMATION:
 - (A) TELEPHONE: (617) 542-5070
 - (B) TELEFAX: (617) 542-8906
 - (C) TELEX: 200154

(2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 1728 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)

- 73 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

ATGAACCGGG	GAGTCCCTTT	TAGGCACTTG	CTTCTGGTGC	TGCAACTGGC	50
GCTCCTCCCA	GCAGCCACTC	AGGGAAACAA	AGTGGTGCTG	GGCAAAAAAG	100
GGGATACAGT	GGAAGTACC	TGTACAGCTT	CCCAGAAGAA	GAGCATACAA	150
TTCCACTGGA	AAAAGTCCAA	CCAGATAAAG	ATTCTGGGAA	ATCAGGGCTC	200
CTTCTTAACT	AAAGGTCCAT	CCAAGCTGAA	TGATCGCGCT	GACTCAAGAA	250
GAAGCCTTTG	GGACCAAGGA	AACTTCCCCC	TGATCATCAA	GAATCTTAAG	300
ATAGAAGACT	CAGATACTTA	CATCTGTGAA	GTGGAGGACC	AGAAGGAGGA	350
GGTGCAATTG	CTAGTGTTTG	GATTGACTGC	CAACTCTGAC	ACCCACCTGC	400
TTCAGGGGCA	GAGCCTGACC	CTGACCTTGG	AGAGCCCCCC	TGGTAGTAGC	450
CCCTCAGTGC	AATGTAGGAG	TCCAAGGGGT	AAAAACATAC	AGGGGGGGAA	500
GACCCCTCTC	GTGTCTCAGC	TGGAGCTCCA	GGATAGTGGC	ACCTGGACAT	550
GCACTGTCTT	GCAGAACCAG	AAGAAGGTGG	AGTTCAAAAT	AGACATCGTG	600
GTGCTAGCTT	TCCAGAAGGC	CTCCAGCATA	GTCTATAAGA	AAGAGGGGGA	650
ACAGGTGGAG	TTCTCCTTCC	CACTCGCCTT	TACAGTTGAA	AAGCTGACGG	700
GCAGTGGCGA	GCTGTGGTGG	CAGGCGGAGA	GGGCTTCCTC	CTCCAAGTCT	750
TGGATCACCT	TTGACCTGAA	GAACAAGGAA	GTGTCTGTAA	AACGGGTTAC	800
CCAGGACCCT	AAGCTCCAGA	TGGGCAAGAA	GCTCCCGCTC	CACCTCACCC	850
TGCCCCAGGC	CTTGCCCTCAG	TATGCTGGCT	CTGGAAACCT	CACCCTGGCC	900
CTTGAAGCGA	AAACAGGAAA	GTTGCATCAG	GAAGTGAACC	TGGTGGTGAT	950
GAGAGCCACT	CAGCTCCAGA	AAAATTTGAC	CTGTGAGGTG	TGGGGACCCA	1000
CCTCCCCTAA	GCTGATGCTG	AGCTTGAAAC	TGGAGAACAA	GGAGGCAAAG	1050
GTCTCGAAGC	GGGAGAAGCC	GGTGTGGGTG	CTGAACCCTG	AGGCGGGGAT	1100
GTGGCAGTGT	CTGCTGAGTG	ACTCGGGACA	GGTCCTGCTG	GAATCCAACA	1150
TCAAGGTTCT	GCCCACATGG	TCCACCCCGG	TGCACGCGGA	TCCCAAACCTC	1200
TGCTACTTGC	TAGATGGAAT	CCTCTTCATC	TACGGAGTCA	TCATCACAGC	1250
CCTGTACCTG	AGAGCAAAAT	TCAGCAGGAG	TGCAGAGACT	GCTGCCAACC	1300
TGCAGGACCC	CAACCAGCTC	TACAATGAGC	TCAATCTAGG	GCGAAGAGAG	1350
GAATATGACG	TCTTGGAGAA	GAAGCGGGCT	CGGGATCCAG	AGATGGGAGG	1400
CAAACAGCAG	AGGAGGAGGA	ACCCCCAGGA	AGGCGTATAC	AATGCACTGC	1450
AGAAAGACAA	GATGCCAGAA	GCCTACAGTG	AGATCGGCAC	AAAAGGCGAG	1500
AGGCGGAGAG	GCAAGGGGCA	CGATGGCCTT	TACCAGGACA	GCCACTTCCA	1550
AGCAGTGCAG	TTCGGGAACA	GAAGAGAGAG	AGAAGGTTCA	GAATCACAA	1600
GGACCCTTGG	GTAAAGAGCC	CGCCCCAAAG	GTGAAAGCAC	CCAGCAGAGT	1650

- 74 -

AGCCAATCCT GTGCCAGCGT CTTCAGCATC CCCACTCTGT GGAGTCCATG	1700
GCCACCCAGT AGCAGCTCCC AGCTCTAA	1728

(2) INFORMATION FOR SEQ ID NO:2:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 1389 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

ATGAACCGGG GAGTCCCTTT TAGGCACTTG CTTCTGGTGC TGCAACTGGC	50
GCTCCTCCCA GCAGCCACTC AGGGAAACAA AGTGGTGCTG GGCAAAAAG	100
GGGATACAGT GGAAGTGACC TGTACAGCTT CCCAGAAGAA GAGCATACAA	150
TTCCACTGGA AAAACTCCAA CCAGATAAAG ATTCTGGGAA ATCAGGGCTC	200
CTTCTTAACT AAAGGTCCAT CCAAGCTGAA TGATCGCGCT GACTCAAGAA	250
GAAGCCTTTG GGACCAAGGA AACTTCCCCC TGATCATCAA GAATCTTAAG	300
ATAGAAGACT CAGATACTTA CATCTGTGAA GTGGAGGACC AGAAGGAGGA	350
GGTGCAATTG CTAGTGTTCC GATTGACTGC CAACTCTGAC ACCCACCTGC	400
TTCAGGGGCA GAGCCTGACC CTGACCTTGG AGAGCCCCCC TGGTAGTAGC	450
CCCTCAGTGC AATGTAGGAG TCCAAGGGGT AAAAACATAC AGGGGGGGAA	500
GACCTCTCC GTGTCTCAGC TGGAGCTCCA GGATAGTGGC ACCTGGACAT	550
GCACTGTCTT GCAGAACCAG AAGAAGGTGG AGTTCAAAAT AGACATCGTG	600
GTGCTAGCTT TCCAGAAGGC CTCCAGCATA GTCTATAAGA AAGAGGGGGA	650
ACAGGTGGAG TTCTCCTTCC CACTCGCCTT TACAGTTGAA AAGCTGACGG	700
GCAGTGGCGA GCTGTGGTGG CAGGCGGAGA GGGCTTCCTC CTCCAAGTCT	750
TGGATCACCT TTGACCTGAA GAACAAGGAA GTGTCTGTAA AACGGGTTAC	800
CCAGGACCCT AAGCTCCAGA TGGGCAAGAA GCTCCCGCTC CACCTCACCC	850
TGCCCCAGGC CTTGCCTCAG TATGCTGGCT CTGGAAACCT CACCCTGGCC	900
CTTGAAGCGA AAACAGGAAA GTTGCATCAG GAAGTGAACC TGGTGGTGAT	950
GAGAGCCACT CAGCTCCAGA AAAATTTGAC CTGTGAGGTG TGGGGACCCA	1000
CCTCCCCTAA GCTGATGCTG AGCTTGAAC TGGAGAACAA GGAGGCAAAG	1050
GTCTCGAAGC GGGAGAAGCC GGTGTGGGTG CTGAACCCTG AGGCGGGGAT	1100
GTGGCAGTGT CTGCTGAGTG ACTCGGGACA GGTCTGCTG GAATCCAACA	1150
TCAAGGTTCT GCCCACATGG TCCACCCCGG TGCACGCGGA TCCGCAGCTC	1200
TGCTATATCC TGGATGCCAT CCTGTTTTTG TATGGTATTG TCCTTACCCT	1250

- 75 -

GCTCTACTGT	CGACTCAAGA	TCCAGGTCCG	AAAGGCAGAC	ATAGCCAGCC	1300
GTGAGAAATC	AGATGCTGTC	TACACGGGCC	TGAACACCCG	GAACCAGGAG	1350
ACATATGAGA	CTCTGAAACA	TGAGAAACCA	CCCCAATAG		1389

(2) INFORMATION FOR SEQ ID NO:3:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 1599 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

ATGAACCGGG	GAGTCCCTTT	TAGGCACTTG	CTTCTGGTGC	TGCAACTGGC	50
GCTCCTCCCA	GCAGCCACTC	AGGGAAACAA	AGTGGTGCTG	GGCAAAAAG	100
GGGATACAGT	GGAAGTGACC	TGTACAGCTT	CCCAGAAGAA	GAGCATACAA	150
TTCCACTGGA	AAAAGTCCAA	CCAGATAAAG	ATTCTGGGAA	ATCAGGGCTC	200
CTTCTTAACT	AAAGGTCCAT	CCAAGCTGAA	TGATCGCGCT	GAAGCAAGAA	250
GAAGCCTTTG	GGACCAAGGA	AACTTCCCCC	TGATCATCAA	GAATCTTAAG	300
ATAGAAGACT	CAGATACTTA	CATCTGTGAA	GTGGAGGACC	AGAAGGAGGA	350
GGTGCAATTG	CTAGTGTTTC	GATTGACTGC	CAACTCTGAC	ACCCACCTGC	400
TTCAGGGGCA	GAGCCTGACC	CTGACCTTGG	AGAGCCCCCC	TGGTAGTAGC	450
CCCTCAGTGC	AATGTAGGAG	TCCAAGGGGT	AAAAACATAC	AGGGGGGGAA	500
GACCCTCTCC	GTGTCTCAGC	TGGAGCTCCA	GGATAGTGGC	ACCTGGACAT	550
GCACTGTCTT	GCAGAACCAG	AAGAAGGTGG	AGTTCAAAAT	AGACATCGTG	600
GTGCTAGCTT	TCCAGAAGGC	CTCCAGCATA	GTCTATAAGA	AAGAGGGGGA	650
ACAGGTGGAG	TTCTCCTTCC	CACTCGCCTT	TACAGTTGAA	AAGCTGACGG	700
GCAGTGGCGA	GCTGTGGTGG	CAGGCGGAGA	GGGCTTCCTC	CTCCAAGTCT	750
TGGATCACCT	TTGACCTGAA	GAACAAGGAA	GTGTCTGTAA	AACGGGTTAC	800
CCAGGACCCT	AAGCTCCAGA	TGGGCAAGAA	GCTCCCGCTC	CACCTCACCC	850
TGCCCCAGGC	CTTGCCCTCAG	TATGCTGGCT	CTGGAAACCT	CACCCTGGCC	900
CTTGAAGCGA	AAACAGGAAA	GTTGCATCAG	GAAGTGAACC	TGGTGGTGAT	950
GAGAGCCACT	CAGCTCCAGA	AAAATTTGAC	CTGTGAGGTG	TGGGGACCCA	1000
CCTCCCCTAA	GCTGATGCTG	AGCTTGAAAC	TGGAGAACAA	GGAGGCAAAG	1050
GTCTCGAAGC	GGGAGAAGCC	GGTGTGGGTG	CTGAACCTTG	AGGCGGGGAT	1100
GTGGCAGTGT	CTGCTGAGTG	ACTCGGGACA	GGTCCTGCTG	GAATCCAACA	1150
TCAAGGTTCT	GCCCACATGG	TCCACCCCGG	TGCACGCGGA	TCCCAAATC	1200

- 76 -

TGCTACCTGC TGGATGGAAT CCTCTTCATC TATGGTGTCA TTCTCACTGC	1250
CTTGTTCTCTG AGAGTGAAGT TCAGCAGGAG CGCAGAGCCC CCCGCGTACC	1300
AGCAGGGCCA GAACCAGCTC TATAACGAGC TCAATCTAGG ACGAAGAGAG	1350
GAGTACGATG TTTTGGACAA GAGACGTGGC CGGGACCCTG AGATGGGGGG	1400
AAAGCCGAGA AGGAAGAACC CTCAGGAAGG CCTGTACAAT GAACTGCAGA	1450
AAGATAAGAT GGCGGAGGCC TACAGTGAGA TTGGGATGAA AGGCGAGCGC	1500
CGGAGGGGCA AGGGGCACGA TGGCCTTTAC CAGGGTCTCA GTACAGCCAC	1550
CAAGGACACC TACGACGCCC TTCACATGCA GGCCCTGCCC CCTCGCTAA	1599

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 575 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Met	Asn	Arg	Gly	Val	Pro	Phe	Arg	His	Leu	Leu	Leu	Val	Leu	Gln	Leu	1	5	10	15
Ala	Leu	Leu	Pro	Ala	Ala	Thr	Gln	Gly	Asn	Lys	Val	Val	Leu	Gly	Lys	20	25	30	
Lys	Gly	Asp	Thr	Val	Glu	Leu	Thr	Cys	Thr	Ala	Ser	Gln	Lys	Lys	Ser	35	40	45	
Ile	Gln	Phe	His	Trp	Lys	Asn	Ser	Asn	Gln	Ile	Lys	Ile	Leu	Gly	Asn	50	55	60	
Gln	Gly	Ser	Phe	Leu	Thr	Lys	Gly	Pro	Ser	Lys	Leu	Asn	Asp	Arg	Ala	65	70	75	80
Asp	Ser	Arg	Arg	Ser	Leu	Trp	Asp	Gln	Gly	Asn	Phe	Pro	Leu	Ile	Ile	85	90	95	
Lys	Asn	Leu	Lys	Ile	Glu	Asp	Ser	Asp	Thr	Tyr	Ile	Cys	Glu	Val	Glu	100	105	110	
Asp	Gln	Lys	Glu	Glu	Val	Gln	Leu	Val	Phe	Gly	Leu	Thr	Ala	Asn		115	120	125	
Ser	Asp	Thr	His	Leu	Leu	Gln	Gly	Gln	Ser	Leu	Thr	Leu	Thr	Leu	Glu	130	135	140	
Ser	Pro	Pro	Gly	Ser	Ser	Pro	Ser	Val	Gln	Cys	Arg	Ser	Pro	Arg	Gly	145	150	155	160
Lys	Asn	Ile	Gln	Gly	Gly	Lys	Thr	Leu	Ser	Val	Ser	Gln	Leu	Glu	Leu	165	170	175	
Gln	Asp	Ser	Gly	Thr	Trp	Thr	Cys	Thr	Val	Leu	Gln	Asn	Gln	Lys	Lys	180	185	190	
Val	Glu	Phe	Lys	Ile	Asp	Ile	Val	Val	Leu	Ala	Phe	Gln	Lys	Ala	Ser	195	200	205	
Ser	Ile	Val	Tyr	Lys	Lys	Glu	Gly	Glu	Gln	Val	Glu	Phe	Ser	Phe	Pro	210	215	220	
Leu	Ala	Phe	Thr	Val	Glu	Lys	Leu	Thr	Gly	Ser	Gly	Glu	Leu	Trp	Trp	225	230	235	240
Gln	Ala	Glu	Arg	Ala	Ser	Ser	Ser	Lys	Ser	Trp	Ile	Thr	Phe	Asp	Leu	245	250	255	
Lys	Asn	Lys	Glu	Val	Ser	Val	Lys	Arg	Val	Thr	Gln	Asp	Pro	Lys	Leu	260	265	270	
Gln	Met	Gly	Lys	Lys	Leu	Pro	Leu	His	Leu	Thr	Leu	Pro	Gln	Ala	Leu	275	280	285	
Pro	Gln	Tyr	Ala	Gly	Ser	Gly	Asn	Leu	Thr	Leu	Ala	Leu	Glu	Ala	Lys	290	295	300	

- 77 -

```

Thr Gly Lys Leu His Gln Glu Val Asn Leu Val Val Met Arg Ala Thr
305          310          315          320
Gln Leu Gln Lys Asn Leu Thr Cys Glu Val Trp Gly Pro Thr Ser Pro
          325          330          335
Lys Leu Met Leu Ser Leu Lys Leu Glu Asn Lys Glu Ala Lys Val Ser
          340          345          350
Lys Arg Glu Lys Pro Val Trp Val Leu Asn Pro Glu Ala Gly Met Trp
          355          360          365
Gln Cys Leu Leu Ser Asp Ser Gly Gln Val Leu Leu Glu Ser Asn Ile
          370          375          380
Lys Val Leu Pro Thr Trp Ser Thr Pro Val His Ala Asp Pro Lys Leu
385          390          395          400
Cys Tyr Leu Leu Asp Gly Ile Leu Phe Ile Tyr Gly Val Ile Ile Thr
          405          410          415
Ala Leu Tyr Leu Arg Ala Lys Phe Ser Arg Ser Ala Glu Thr Ala Ala
          420          425          430
Asn Leu Gln Asp Pro Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg
          435          440          445
Arg Glu Glu Tyr Asp Val Leu Glu Lys Lys Arg Ala Arg Asp Pro Glu
          450          455          460
Met Gly Gly Lys Gln Gln Arg Arg Arg Asn Pro Gln Glu Gly Val Tyr
465          470          475          480
Asn Ala Leu Gln Lys Asp Lys Met Pro Glu Ala Tyr Ser Glu Ile Gly
          485          490          495
Thr Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln
          500          505          510
Asp Ser His Phe Gln Ala Val Gln Phe Gly Asn Arg Arg Glu Arg Glu
          515          520          525
Gly Ser Glu Leu Thr Arg Thr Leu Gly Leu Arg Ala Arg Pro Lys Gly
          530          535          540
Glu Ser Thr Gln Gln Ser Ser Gln Ser Cys Ala Ser Val Phe Ser Ile
555          550          565          560
Pro Thr Leu Trp Ser Pro Trp Pro Pro Ser Ser Ser Ser Gln Leu
          565          570          575

```

(2) INFORMATION FOR SEQ ID NO:5:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 462 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

```

Met Asn Arg Gly Val Pro Phe Arg His Leu Leu Leu Val Leu Gln Leu
 1          5          10          15
Ala Leu Leu Pro Ala Ala Thr Gln Gly Asn Lys Val Val Leu Gly Lys
          20          25          30
Lys Gly Asp Thr Val Glu Leu Thr Cys Thr Ala Ser Gln Lys Lys Ser
          35          40          45
Ile Gln Phe His Trp Lys Asn Ser Asn Gln Ile Lys Ile Leu Gly Asn
          50          55          60
Gln Gly Ser Phe Leu Thr Lys Gly Pro Ser Lys Leu Asn Asp Arg Ala
          65          70          75          80
Asp Ser Arg Arg Ser Leu Trp Asp Gln Gly Asn Phe Pro Leu Ile Ile
          85          90          95
Lys Asn Leu Lys Ile Glu Asp Ser Asp Thr Tyr Ile Cys Glu Val Glu
          100          105          110
Asp Gln Lys Glu Glu Val Gln Leu Val Phe Gly Leu Thr Ala Asn
          115          120          125
Ser Asp Thr His Leu Leu Gln Gly Gln Ser Leu Thr Leu Thr Leu Glu
          130          135          140
Ser Pro Pro Gly Ser Ser Pro Ser Val Gln Cys Arg Ser Pro Arg Gly
145          150          155          160

```

- 78 -

```

Lys Asn Ile Gln Gly Gly Lys Thr Leu Ser Val Ser Gln Leu Glu Leu
      165      170      175
Gln Asp Ser Gly Thr Trp Thr Cys Thr Val Leu Gln Asn Gln Lys Lys
      180      185      190
Val Glu Phe Lys Ile Asp Ile Val Val Leu Ala Phe Gln Lys Ala Ser
      195      200      205
Ser Ile Val Tyr Lys Lys Glu Gly Glu Gln Val Glu Phe Ser Phe Pro
      210      215      220
Leu Ala Phe Thr Val Glu Lys Leu Thr Gly Ser Gly Glu Leu Trp Trp
      225      230      235      240
Gln Ala Glu Arg Ala Ser Ser Ser Lys Ser Trp Ile Thr Phe Asp Leu
      245      250      255
Lys Asn Lys Glu Val Ser Val Lys Arg Val Thr Gln Asp Pro Lys Leu
      260      265      270
Gln Met Gly Lys Lys Leu Pro Leu His Leu Thr Leu Pro Gln Ala Leu
      275      280      285
Pro Gln Tyr Ala Gly Ser Gly Asn Leu Thr Leu Ala Leu Glu Ala Lys
      290      295      300
Thr Gly Lys Leu His Gln Glu Val Asn Leu Val Val Met Arg Ala Thr
      305      310      315      320
Gln Leu Gln Lys Asn Leu Thr Cys Glu Val Trp Gly Pro Thr Ser Pro
      325      330      335
Lys Leu Met Leu Ser Leu Lys Leu Glu Asn Lys Glu Ala Lys Val Ser
      340      345      350
Lys Arg Glu Lys Pro Val Trp Val Leu Asn Pro Glu Ala Gly Met Trp
      355      360      365
Gln Cys Leu Leu Ser Asp Ser Gly Gln Val Leu Leu Glu Ser Asn Ile
      370      375      380
Lys Val Leu Pro Thr Trp Ser Thr Pro Val His Ala Asp Pro Gln Leu
      385      390      395      400
Cys Tyr Ile Leu Asp Ala Ile Leu Phe Leu Tyr Gly Ile Val Leu Thr
      405      410      415
Leu Leu Tyr Cys Arg Leu Lys Ile Gln Val Arg Lys Ala Asp Ile Ala
      420      425      430
Ser Arg Glu Lys Ser Asp Ala Val Tyr Thr Gly Leu Asn Thr Arg Asn
      435      440      445
Gln Glu Thr Tyr Glu Thr Leu Lys His Glu Lys Pro Pro Gln
      450      455      460      462

```

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 532 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

```

Met Asn Arg Gly Val Pro Phe Arg His Leu Leu Leu Val Leu Gln Leu
  1      5      10      15
Ala Leu Leu Pro Ala Ala Thr Gln Gly Asn Lys Val Val Leu Gly Lys
      20      25      30
Lys Gly Asp Thr Val Glu Leu Thr Cys Thr Ala Ser Gln Lys Lys Ser
      35      40      45
Ile Gln Phe His Trp Lys Asn Ser Asn Gln Ile Lys Ile Leu Gly Asn
      50      55      60
Gln Gly Ser Phe Leu Thr Lys Gly Pro Ser Lys Leu Asn Asp Arg Ala
      65      70      75      80
Asp Ser Arg Arg Ser Leu Trp Asp Gln Gly Asn Phe Pro Leu Ile Ile
      85      90      95
Lys Asn Leu Lys Ile Glu Asp Ser Asp Thr Tyr Ile Cys Glu Val Glu
      100      105      110
Asp Gln Lys Glu Glu Val Gln Leu Leu Val Phe Gly Leu Thr Ala Asn
      115      120      125

```


- 79 -

```

Ser Asp Thr His Leu Leu Gln Gly Gln Ser Leu Thr Leu Thr Leu Glu
130      135      140
Ser Pro Pro Gly Ser Ser Pro Ser Val Gln Cys Arg Ser Pro Arg Gly
145      150      155      160
Lys Asn Ile Gln Gly Gly Lys Thr Leu Ser Val Ser Gln Leu Glu Leu
165      170      175
Gln Asp Ser Gly Thr Trp Thr Cys Thr Val Leu Gln Asn Gln Lys Lys
180      185      190
Val Glu Phe Lys Ile Asp Ile Val Val Leu Ala Phe Gln Lys Ala Ser
195      200      205
Ser Ile Val Tyr Lys Lys Glu Gly Glu Gln Val Glu Phe Ser Phe Pro
210      215      220
Leu Ala Phe Thr Val Glu Lys Leu Thr Gly Ser Gly Glu Leu Trp Trp
225      230      235      240
Gln Ala Glu Arg Ala Ser Ser Ser Lys Ser Trp Ile Thr Phe Asp Leu
245      250      255
Lys Asn Lys Glu Val Ser Val Lys Arg Val Thr Gln Asp Pro Lys Leu
260      265      270
Gln Met Gly Lys Lys Leu Pro Leu His Leu Thr Leu Pro Gln Ala Leu
275      280      285
Pro Gln Tyr Ala Gly Ser Gly Asn Leu Thr Leu Ala Leu Glu Ala Lys
290      295      300
Thr Gly Lys Leu His Gln Glu Val Asn Leu Val Val Met Arg Ala Thr
305      310      315      320
Gln Leu Gln Lys Asn Leu Thr Cys Glu Val Trp Gly Pro Thr Ser Pro
325      330      335
Lys Leu Met Leu Ser Leu Lys Leu Glu Asn Lys Glu Ala Lys Val Ser
340      345      350
Lys Arg Glu Lys Pro Val Trp Val Leu Asn Pro Glu Ala Gly Met Trp
355      360      365
Gln Cys Leu Leu Ser Asp Ser Gly Gln Val Leu Leu Glu Ser Asn Ile
370      375      380
Lys Val Leu Pro Thr Trp Ser Thr Pro Val His Ala Asp Pro Lys Leu
385      390      395      400
Cys Tyr Leu Leu Asp Gly Ile Leu Phe Ile Tyr Gly Val Ile Leu Thr
405      410      415
Ala Leu Phe Leu Arg Val Lys Phe Ser Arg Ser Ala Glu Pro Pro Ala
420      425      430
Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg
435      440      445
Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu
450      455      460
Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn
465      470      475      480
Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met
485      490      495
Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly
500      505      510
Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala
515      520      525
Leu Pro Pro Arg
530

```

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 33 bases
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: nucleic acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

- 80 -

CGCGGGGTGA CCGTGCCCTC CAGCAGCTTG GGC

33

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 50 bases
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: nucleic acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

CGCGGGGATC CGTCGTCCAG AGCCCGTCCA GCTCCCCGTC CTGGGCCTCA

50

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 33 bases
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: nucleic acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

CGCGGGCGGC CGCGACGCCG GCCAAGACAG CAC

33

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 33 bases
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: nucleic acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

CGCGTTGACG AGCAGCCAGT TGGGCAGCAG CAG

33

(2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 15 bases
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: nucleic acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

CGCGGGCGGC CGCTA

15

- 81 -

(2) INFORMATION FOR SEQ ID NO:12:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 42 bases
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: nucleic acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

CGCGGGCTCG TTATAGAGCT GGTTCTGGCG CTGCTTCTTC TG

42

(2) INFORMATION FOR SEQ ID NO:13:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 48 bases
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: nucleic acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

CGCGGGGAGC TCGTTATAGA GCTGGTTTGC CGCCGAATTC TTATCCCG

48

(2) INFORMATION FOR SEQ ID NO:14:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 33 bases
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: nucleic acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

CGCGGGGCGG CCACGCGTCC TCGCCAGCAC ACA

33

(2) INFORMATION FOR SEQ ID NO:15:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 36 bases
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: nucleic acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

CGCGGGACGC GTTTCAGCCG TCCTCGCCAG CACACA

36

- 82 -

(2) INFORMATION FOR SEQ ID NO:16:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 33 bases
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: nucleic acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

CGCGGGACGC GTGACCCTGA GATGGGGGGA AAG

33

(2) INFORMATION FOR SEQ ID NO:17:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 33 bases
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: nucleic acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

CGCGGGACGC GTATTGGGAT GAAAGGCGAG CGC

33

(2) INFORMATION FOR SEQ ID NO:18:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 26 bases
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: nucleic acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

CCCGGATCCC AGCATGGGCA GCTCTT

26

(2) INFORMATION FOR SEQ ID NO:19:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 42 bases
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: nucleic acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

CGCGGGGCGG CCGCTTTAGT TATTACTGTT GACATGGTCG TT

42

- 83 -

(2) INFORMATION FOR SEQ ID NO:20:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 30 bases
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: nucleic acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

GCGGGGGGAT CCCACTGTCC AAGCTCCCAG

30

(2) INFORMATION FOR SEQ ID NO:21:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 32 bases
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: nucleic acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

GCGGGGGCGG CCGCCTAAAT ACGGTTCTGG TC

32

(2) INFORMATION FOR SEQ ID NO:22:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 31 bases
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: nucleic acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

TCAGAAAGAG ACAACCTGAA GAAACCAACA A

31

(2) INFORMATION FOR SEQ ID NO:23:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 31 bases
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: nucleic acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

TTGTTGTTT CTCAGGTTG TGTCTTCTG A

31

- 84 -

(2) INFORMATION FOR SEQ ID NO:24:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 171 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: amino acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

```

Met Glu His Ser Thr Phe Leu Ser Gly Leu Val Leu Ala Thr Leu Leu
      5      10      15
Ser Gln Val Ser Pro Phe Lys Ile Pro Ile Glu Glu Leu Glu Asp Arg
      20      25      30
Val Phe Val Asn Cys Asn Thr Ser Ile Thr Trp Val Glu Gly Thr Val
      35      40      45
Gly Thr Leu Leu Ser Asp Ile Thr Arg Leu Asp Leu Gly Lys Arg Ile
      50      55      60
Leu Asp Pro Arg Gly Ile Tyr Arg Cys Asn Gly Thr Asp Ile Tyr Lys
      65      70      75      80
Asp Lys Glu Ser Thr Val Gln Val His Tyr Arg Met Cys Gln Ser Cys
      85      90      95
Val Glu Leu Asp Pro Ala Thr Val Ala Gly Ile Ile Val Thr Asp Val
      100      105      110
Ala Ile Thr Leu Leu Leu Ala Leu Gly Val Phe Cys Phe Ala Gly His
      115      120      125
Glu Thr Gly Arg Leu Ser Gly Ala Ala Asp Thr Gln Ala Leu Leu Arg
      130      135      140
Asn Asp Gln Val Tyr Gln Pro Leu Arg Asp Arg Asp Ala Gln Tyr
      145      150      155      160
Ser His Leu Gly Gly Asn Trp Ala Arg Asn Lys
      165      170

```

(2) INFORMATION FOR SEQ ID NO:25:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 182 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: amino acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

```

Met Glu Gln Gly Lys Gly Leu Ala Val Leu Ile Leu Ala Ile Ile Leu
      5      10      15
Leu Gln Gly Thr Leu Ala Gln Ser Ile Lys Gly Asn His Leu Val Lys
      20      25      30
Val Tyr Asp Tyr Gln Glu Asp Gly Ser Val Leu Leu Thr Cys Asp Ala
      35      40      45
Glu Ala Lys Asn Ile Thr Trp Phe Lys Asp Gly Lys Met Ile Gly Phe
      50      55      60
Leu Thr Glu Asp Lys Lys Lys Trp Asn Leu Gly Ser Asn Ala Lys Asp
      65      70      75      80
Pro Arg Gly Met Tyr Gln Cys Lys Gly Ser Gln Asn Lys Ser Lys Pro
      85      90      95
Leu Gln Val Tyr Arg Met Cys Gln Asn Cys Ile Glu Leu Asn Ala
      100      105      110
Ala Thr Ile Ser Gly Phe Leu Phe Ala Glu Ile Val Ser Ile Phe Val
      115      120      125
Leu Ala Val Gly Val Tyr Phe Ile Ala Gly Gln Asp Gly Val Arg Gln
      130      135      140

```

- 85 -

```

Ser Arg Ala Ser Asp Lys Gln Thr Leu Leu Pro Asn Asp Gln Leu Tyr
145          150          155          160
Gln Pro Leu Lys Asp Arg Glu Asp Asp Gln Tyr Ser His Leu Gln Gly
          165          170          175
Asn Gln Leu Arg Arg Asn
          180

```

(2) INFORMATION FOR SEQ ID NO:26:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 220 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: amino acids

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

```

Met Pro Gly Gly Leu Glu Ala Leu Arg Ala Leu Pro Leu Leu Leu Phe
          5          10          15
Leu Ser Tyr Ala Cys Leu Gly Pro Gly Cys Gln Ala Leu Arg Val Glu
          20          25          30
Gly Gly Pro Pro Ser Leu Thr Val Asn Leu Gly Glu Glu Ala Arg Leu
          35          40          45
Thr Cys Glu Asn Asn Gly Arg Asn Pro Asn Ile Thr Trp Trp Phe Ser
          50          55          60
Leu Gln Ser Asn Ile Thr Trp Pro Pro Val Pro Leu Gly Pro Gly Gln
          65          70          75          80
Gly Thr Thr Gly Gln Leu Phe Phe Pro Glu Val Asn Lys Asn Thr Gly
          85          90          95
Ala Cys Thr Gly Cys Gln Val Ile Glu Asn Asn Ile Leu Lys Arg Ser
          100          105          110
Cys Gly Thr Tyr Leu Arg Val Arg Asn Pro Val Pro Arg Pro Phe Leu
          115          120          125
Asp Met Gly Glu Gly Thr Lys Asn Arg Ile Ile Thr Ala Glu Gly Ile
          130          135          140
Ile Leu Leu Phe Cys Ala Val Val Pro Gly Thr Leu Leu Leu Phe Arg
          145          150          155          160
Lys Arg Trp Gln Asn Glu Lys Phe Gly Val Asp Met Pro Asp Asp Tyr
          165          170          175
Glu Asp Glu Asn Leu Tyr Glu Gly Leu Asn Leu Asp Asp Cys Ser Met
          180          185          190
Tyr Glu Asp Ile Ser Arg Gly Leu Gln Gly Thr Tyr Gln Asp Val Gly
          195          200          205
Asn Leu His Ile Gly Asp Ala Gln Leu Glu Lys Pro
          210          215          220

```

(2) INFORMATION FOR SEQ ID NO:27:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 228 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: amino acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:

```

Met Ala Thr Leu Val Leu Ser Ser Met Pro Cys His Trp Leu Leu Phe
          5          10          15
Leu Leu Leu Leu Phe Ser Gly Glu Pro Val Pro Ala Met Thr Ser Ser
          20          25          30

```

- 86 -

[illegible]

- 87 -

Claims

1. A method of directing a cellular immune response against an HIV-infected cell in a mammal, said method comprising administering to said mammal an effective amount of therapeutic cells, said therapeutic cells expressing a membrane-bound, proteinaceous chimeric receptor comprising (a) an extracellular portion which includes a fragment of CD4 which is capable of specifically recognizing and binding said HIV-infected cell but which does not mediate HIV infection and (b) an intracellular portion which is capable of signalling said therapeutic cell to destroy said receptor-bound HIV-infected cell.
2. The method of claim 1, wherein said CD4 fragment consists of amino acids 1-394 or amino acids 1-200.
3. The method of claim 1, wherein said CD4 fragment is separated from said intracellular portion by the CD7 transmembrane domain shown in Fig. 26 or by the hinge, CH2, and CH3 domains of the human IgG1 molecule shown in Fig. 25.
4. The method of claim 1, wherein said CD4 fragment is separated from said therapeutic cell membrane by at least 48 angstroms or by at least 72 angstroms.
5. The method of claim 1, wherein said intracellular portion is the signal-transducing portion of a T cell receptor protein, a B cell receptor protein, or an Fc receptor protein.
6. The method of claim 5, wherein said T cell receptor protein is ζ .

- 88 -

7. The method of claim 1, wherein said therapeutic cells are selected from the group consisting of: (a) T lymphocytes; (b) cytotoxic T lymphocytes; (c) natural killer cells; (d) neutrophils; (e) granulocytes; 5 (f) macrophages; (g) mast cells; (h) HeLa cells; and (i) embryonic stem cells (ES).

8. The method of claim 1, wherein said receptor includes a CD7 transmembrane portion, a CD5 transmembrane 10 portion, or a CD34 transmembrane portion.

9. The method of claim 1, wherein said CD4 fragment is separated from said therapeutic cell membrane by one or more proteinaceous alpha helices. 15

10. A cell which expresses a proteinaceous membrane-bound chimeric receptor, said receptor comprising (a) an extracellular portion which includes a fragment of CD4 which is capable of specifically 20 recognizing and binding said HIV-infected cell but which does not mediate HIV infection and (b) an intracellular portion which is capable of signalling said cell to destroy a receptor-bound HIV-infected cell.

25 11. The cell of claim 10, wherein said CD4 fragment consists of amino acids 1-394 or amino acids 1-200.

12. The cell of claim 10, wherein said CD4 30 fragment is separated from said intracellular portion by the CD7 transmembrane domain shown in Fig. 26 or by the hinge, CH2, and CH3 domains of the human IgG1 molecule shown in Fig. 25.

35 13. The cell of claim 10, wherein said CD4 fragment is separated from said therapeutic cell membrane by at least 48 angstroms or by at least 72 angstroms.

- 89 -

14. The cell of claim 10, wherein said intracellular portion is the signal-transducing portion of a T cell receptor protein, a B cell receptor protein, or an Fc receptor protein.

5

15. The cell of claim 14, wherein said T cell receptor protein is ζ .

16. The cell of claim 10 wherein said receptor
10 includes a CD7 transmembrane portion, a CD5 transmembrane portion, or a CD34 transmembrane portion.

17. The cell of claim 10, wherein said CD4
fragment is separated from said therapeutic cell membrane
15 by one or more proteinaceous alpha helices.

18. DNA encoding a chimeric receptor of claim 10.

19. A vector comprising the chimeric receptor DNA
20 of claim 18.

1 / 27

FIG. 1a





FIG. 1b



2/27

FIG. 2









FIG. 3



3/27

FIG. 4a**FIG. 4b**

4 / 27

FIG. 4c**FIG. 4d**

5/27

FIG. 5a






FIG. 5b



6/27

FIG. 5c



7/27

FIG. 6a





FIG. 6b



8/27

FIG. 7a





FIG. 7b



9/27

FIG. 8a





FIG. 8b



10/27

FIG. 9a





FIG. 9b

% CHROMIUM
RELEASED

11/27

FIG. 9c







FIG. 9d



12/27

FIG. 10a**FIG. 10b**

13/27

FIG. 10c





FIG. 10d



14/27

FIG. 10e





FIG. 10f



15/27

FIG. 11a






FIG. 11b



16/27

**FIG. 12**

17/27

FIG. 13a





FIG. 13b



18/27

FIG. 14a





FIG. 14b



19/27

FIG. 15a




FIG. 15b





FIG. 15c



20/27

FIG. 15d





FIG. 15e



21/27

FIG.16 (Seq. ID No: 24)

1 MEHSTFLSGL VLATLLSQVS PFKIPIEELE DRVFN CNTS ITWVEGTVGT
 51 LLSDITRLDL GKRILDPRGI YRCNGTDIYK DKESTVQVHY RMCQSCVELD
 101 PATVAGIIVT DVIATLLLLAL GVFCFAGHET GRLSGAADTQ ALLRNDQVYQ
 151 PLRDRDDAQY SHLGGNWARN K*

FIG.17 (Seq ID NO: 25)

1 MEQGKGLAVL ILAIILLQGT LAQSIKGNHL VKVYDYQEDG SVLLTCDAEA
 51 KNITWFKDGK MIGFLTEDKK KWNLG SNAKD PRGMYQCKGS QNKS KPLQVY
 101 YRMCQNCIEL NAATISGFLF AEIVSIFVLA VGVYFIAGQD GVRQSRASDK
 151 QTL LPNDQLY QPLKDREDDQ YSHLQGNQLR RN*

FIG.18 (Seq ID No: 26)

1 MPGGLEALRA LPLLLFLSYA CLGPGCQALR VEGGPPSLTV NLGEEARLTC
 51 ENNGRNP NIT WWFSLQSNIT WPPVPLGPGQ GTTGQLFFPE VNKNTGACTG
 101 CQVIENNILK RSCGTYLRVR NPVPRPFLDM GEGTKNRIIT AEGIILLFCA
 151 VVPGTLL LFR KRWQNEKFGV DMPDDYEDEN LYEGLNLDDC SMYEDISRGL
 201 QGT YQDVGNL HIGDAQLEKP *

FIG.19 (Seq ID No: 27)

1 MATLV LSSMP CHWLLFLLLL FS GEPVPAMT SSDLPLNFQG SPCSQIWQHP
 51 RFAAKKRSSM VKFHCYTNHS GALTWFRKRG SQQPQELVSE EGRIVQTONG
 101 SVYTLTIQNI QYEDNGIYFC KQKCDSANHN VTDSCGTELL VLG FSTLDQL
 151 KRRNTLKDGI ILIQTL LLIIL FIIVP IFLLL DKDDGKAGME EDHTYEG LNI
 201 DQTATYEDIV TLRTGEVKWS VGEHPGQE*

22/27




FIG. 20a

FIG. 20b

FIG. 20c

FIG. 20d

FIG. 20e

BamHI/BstY1



Bgl2/BstY1

G GAT CCC AAG GCC AGG CTA AAG CCG AAG CCG CGA AGG CCG AGG CTA AGG CCG AAG CAG ATC IG

DPKAEAKAEAKAEADL

FIG. 28

23/27

**FIG. 21****FIG. 22**

24/27

D1-D4 of CD4

Nucleic Acid Sequence

GCCTGTTTGA	GAAGCAGCGG	GCAAGAAAGA	CGCAAGCCCA	GAGGCCCTGC	51
CATTTCTGTG	GGCTCAGGTC	CCTACTGGCT	CAGGCCCTG	CCTCCCTCGG	101
CAAGGCCACA	ATGAACCGGG	GAGTCCCTTT	TAGGCACTTG	CTTCTGGTGC	151
TGCAACTGGC	GCTCCTCCCA	GCAGCCACTC	AGGGAAACAA	AGTGGTGCTG	201
GGCAAAAAG	GGGATACAGT	GGAAGTACC	TGTACAGCTT	CCCAGAAGAA	251
GAGCATACAA	TTCCACTGGA	AAAAGTCCAA	CCAGATAAAG	ATTCTGGGAA	301
ATCAGGGCTC	CTTCTTAACT	AAAGGTCCAT	CCAAGCTGAA	TGATCGCGCT	351
GAATCTTAAG	GAAGCCTTTG	GGACCAAGGA	AACTTCCCCC	TGATCATCAA	401
AGAAGGAGGA	GGTGCAATTG	CAGATACTTA	CATCTGTGAA	GTGGAGGACC	451
ACCCACCTGC	TTCAGGGGCA	GAGCCTGACC	CTGACCTTGG	AGAGCCCCCC	501
TGGTAGTAGC	CCCTCAGTGC	AATGTAGGAG	TCCAAGGGGT	AAAAACATAC	551
AGGGGGGGAA	GACCTCTCC	GTGTCTCAGC	TGGAGCTCCA	GGATAGTGGC	601
ACCTGGACAT	GCACTGTCTT	GCAGAACCAG	AAGAAGGTGG	AGTTCAAAAT	651
AGACATCGTG	GTGCTAGCTT	TCCAGAAGGC	CTCCAGCATA	GTCTATAAGA	701
AAGAGGGGGA	ACAGGTGGAG	TTCTCCTTCC	CACTCGCCTT	TACAGTTGAA	751
AAGCTGACGG	GCAGTGGCGA	GCTGTGGTGG	CAGGCGGAGA	GGGCTTCCTC	801
CTCCAAGTCT	TGGATCACCT	TTGACCTGAA	GAACAAGGAA	GTGTCTGTAA	851
AACGGGTAC	CCAGGACCCT	AAGCTCCAGA	TGGGCAAGAA	GCTCCCCGCTC	901
CACCTCACCC	TGCCCCAGGC	CTTGCCTCAG	TATGCTGGCT	CTGGAAACCT	951
CACCCTGGCC	CTTGAAGCGA	AAACAGGAAA	GTTGCATCAG	GAAGTGAACC	1001
TGGTGGTGAT	GAGAGCCACT	CAGCTCCAGA	AAAATTTGAC	CTGTGAGGTG	1051
TGGGGACCCA	CCTCCCCTAA	GCTGATGCTG	AGCTTGAAAC	TGGAGAACAA	1101
GGAGGCAAAG	GTCTCGAAGC	GGGAGAAGCC	GGTGTGGGTG	CTGAACCCTG	1151
AGGCGGGGAT	GTGGCAGTGT	CTGCTGAGTG	ACTCGGGACA	GGTCCTGCTG	1201
GAATCCAACA	TCAAGGTTCT	GCCCACATGG	TCCACCCCGG	TGCACGCGGA	1251
TCCC (SEQ ID NO: 28)					1301

Amino Acid Sequence

MNRGVPRHL	LLVLQLALLP	AATQGNKVVL	GKKGDTVELT	CTASQKKSIIQ	51
FHWKNSNQIK	ILGNQGSFLT	KGPSKLNDRA	DSRRSLWDQG	NFPLIIKNLK	101
IEDSDTYICE	VEDQKEEVQL	LVFGLTANS	THLLQGQSLT	LTLESPPGSS	151
PSVQCRSPRG	KNIQGGKTL	VSQLELQDSG	TWTCTVLQNG	KKVEFKIDIV	201
VLAFOKASSI	VYKKEGEQVE	FSFPLAFTVE	KLTGSGELWW	QAERASSSKS	251
WITFDLKNKE	VSVKRVTQDP	KLQMGKKLPL	HLTLPQALPQ	YAGSGNLTLA	301
LEAKTGKLHQ	EVNLVVMRAT	QLQKNLTCEV	WGPTSPKLML	SLKLENKEAK	351
VSKREKPVVW	LNPEAGMWQC	LLSDSGQVLL	ESNIKVLPTW	STPVHADP	

(SEQ ID NO: 29)

FIG. 23

25/27

D1-D2 of CD4

Nucleic Acid Sequence

GCCTGTTTGA	GAAGCAGCGG	GCAAGAAAGA	CGCAAGCCCA	GAGGCCCTGC	51
CATTTCTGTG	GGCTCAGGTC	CCTACTGGCT	CAGGCCCTTG	CCTCCCTCGG	101
CAAGGCCACA	ATGAACCGGG	GAGTCCCTTT	TAGGCACTTG	CTTCTGGTGC	151
TGCAACTGGC	GCTCCTCCCA	GCAGCCACTC	AGGGAAACAA	AGTGGTGCTG	201
GGCAAAAAG	GGGATACAGT	GGAACTGACC	TGTACAGCTT	CCCAGAAGAA	251
GAGCATACAA	TTCCACTGGA	AAAACCTCCAA	CCAGATAAAG	ATTCTGGGAA	301
ATCAGGGCTC	CTTCTTAACT	AAAGGTCCAT	CCAAGCTGAA	TGATCGCGCT	351
GACTCAAGAA	GAAGCCTTTG	GGACCAAGGA	AACCTCCCCC	TGATCATCAA	401
GAATCTTAAG	ATAGAAGACT	CAGATACTTA	CATCTGTGAA	GTGGAGGACC	451
AGAAGGAGGA	GGTGCAATTG	CTAGTGTTTCG	GATTGACTGC	CAACTCTGAC	501
ACCCACCTGC	TTCAGGGGCA	GAGCCTGACC	CTGACCTTGG	AGAGCCCCCC	551
TGGTAGTAGC	CCCTCAGTGC	AATGTAGGAG	TCCAAGGGGT	AAAAACATAC	601
AGGGGGGGAA	GACCCTCTCC	GTGTCTCAGC	TGGAGCTCCA	GGATAGTGGC	651
ACCTGGACAT	GCACTGTCTT	GCAGAACCAG	AAGAAGGTGG	AGTTCAAAT	701
AGACATCGTG	GTGCTAGCT	(SEQ ID NO: 30)			

Amino Acid Sequence

MNRGVFPRHL	LLVLQLALLP	AATQGNKVVL	GKKGDTVELT	CTASQKRSIQ	51
FHWKNSNQIK	ILGNQGSFLT	KGPSKLNDR	DSRRSLWDQG	NFPLIIKNLK	101
IEDSDTYICE	VEDQKEEVQL	LVFGLTANS	THLLQGQSLT	LTLESPPGSS	151
PSVQCRSPRG	KNIQGGKTLS	VSQLELQDSG	TWTCTVLQNO	KKVEFKIDIV	201
VLA (SEQ ID NO: 31)					

FIG. 24

26/27

Hinge, CH₂, and CH₃ Domains of Human IgG1

Nucleic Acid Sequence

GCTAGCAGAG	CCCAAATCTT	GTGACAAAAC	TCACACATGC	CCACCGTGCC	51
CAGCACCTGA	ACTCCTGGGG	GGACCGTCAG	TCTTCCTCTT	CCCCCAGAAA	101
CCCAAGGACA	CCCTCATGAT	CTCCCGGACC	CCTGAGGTCA	CATGCGTGGT	151
GGTGGACGTG	AGCCACGAAG	ACCCTGAGGT	CAAGTTC AAC	TGGTACGTGG	201
ACGGCGTGGA	GGTGCATAAT	GCCAAGACAA	AGCCGCGGGA	GGAGCAGTAC	251
AACAGCACGT	ACCGGGTGGT	CAGCGTCCTC	ACCGTCCTGC	ACCAGGACTG	301
GCTGAATGGC	AAGGAGTACA	AGTGCAAGGT	CTCCAACAAA	GCCCTCCAG	351
CCCCCATCGA	GAAAACCATC	TCCAAAGCCA	AAGGGCAGCC	CCGAGAACCA	401
CAGGTGTACA	CCCTGCCCCC	ATCCCGGGAT	GAGCTGACCA	AGAACCAGGT	451
CAGCCTGACC	TGCCTGGTCA	AAGGCTTCTA	TCCCAGCGAC	ATCGCCGTGG	501
AGTGGGAGAG	CAATGGGCAG	CCGGAGAACA	ACTACAAGAC	CACGCCTCCC	551
GTGCTGGACT	CCGACGGCTC	CTTCTTCCTC	TACAGCAAGC	TCACCGTGGA	601
CAAGAGCAGG	TGGCAGCAGG	GGAACGTCTT	CTCATGCTCC	GTGATGCATG	651
AGGCTCTGCA	CAACCACTAC	ACGCAGAAGA	GCCTCTCCCT	GTCTCCGGGG	701
CTGCAACTGG	ACGAGACCTG	TGCTGAGGCC	CAGGACGGGG	AGCTGGACGG	751
GCTCTGGACG	ACGGATCC	(SEQ ID NO: 32)			

Amino Acid Sequence

EPKSCDKTHT	CPPCPAPELL	GGPSVFLFPP	KPKDTLMISR	TPEVTCVVVD	51
VSHEDPEVKF	NWYVDGVEVH	NAKTKPREEQ	YNSTYRVVSV	LTVLHQDWLN	101
GKEYKCKVSN	KALPAPIEKT	ISKAKGQPRE	PQVYTLPPSR	DELTKNQVSL	151
TCLVKGFYPS	DIAVEWESNG	QPENNYKTP	PVLDSGDSFF	LYSKLTVDKS	201
RWQQGNVFSC	SVMHEALHNH	YTQKSLSLSP	GLQLDETCAE	AQDGELDGLW	251
TTDP	(SEQ ID NO: 33)				

FIG. 25

27/27

CD7 Transmembrane Domain

Nucleic Acid Sequence

CCAAGGGCCT	CTGCCCTCCC	TGCCCCACCG	ACAGGCTCCG	CCCTCCCTGA	51
CCCGCAGACA	GCCTCTGCCC	TCCCTGACCC	GCCAGCAGCC	TCTGCCCTCC	101
CTGCGGCCCT	GGCGGTGATC	TCCTTCCTCC	TCGGGCTGGG	CCTGGGGGTG	151
GCGTGTGTGC	TGGCGAGGAC	GCGT	(SEQ ID NO: 34)		

Amino Acid Sequence

PRASALPAPP	TGSALPDPQT	ASALPDPPAA	SALPAALAVI	SFLLGLGLGV	51
ACVLARTR	(SEQ ID NO: 35)				

FIG. 26

Zeta Intracellular Domain

Nucleic Acid Sequence

ACGCGTTTCA	GCAGGAGCGC	AGAGCCCCCC	GCGTACCAGC	AGGGCCAGAA	51
CCAGCTCTAT	AACGAGCTCA	ATCTAGGACG	AAGAGAGGAG	TACGATGTTT	101
TGGACAAGAG	ACGTGGCCGG	GACCCTGAGA	TGGGGGGAAA	GCCGAGAAGG	151
AAGAACCCTC	AGGAAGGCCT	GTACAATGAA	CTGCAGAAAG	ATAAGATGGC	201
GGAGGCCTAC	AGTGAGATTG	GGATGAAAGG	CGAGCGCCGG	AGGGGCAAGG	251
GGCACGATGG	CCTTTACCAG	GGTCTCAGTA	CAGCCACCAA	GGACACCTAC	301
GACGCCCTTC	ACATGCAGGC	CCTGCCCCCT	CGCTAAAGCG	GCCGC	
(SEQ ID NO: 36)					

Amino Acid Sequence

TRFSRSAEPP	AYQQGQNQLY	NELNLGRREE	YDVLDKRRGR	DPENGGKPRR	51
KNPQEGLYNE	LQDKMAEAY	SEIGMKGERR	RGKGHDGLYQ	GLSTATKDTY	101
DALHMQALPP	R	(SEQ ID NO: 37)			

FIG. 27

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US95/00454

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : A01N 63/00; A61K 39/00; C07H 17/00; C12N 5/00, 15/00

US CL : 424/93.21; 435/172.1, 172.3, 240.2, 240.21, 320.1; 536/23.1, 23.4, 23.5

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/93.21; 435/172.1, 172.3, 240.2, 240.21, 320.1; 536/23.1, 23.4, 23.5

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP, A, 0,394,827 (KARJALAINEN ET AL.) 31 OCTOBER 1990, see entire document.	1-19
Y	NATURE, Volume 312, issued 27 December 1984, A.G. Dalgleish et al., "The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus", pages 763-767, see entire document.	1-19
Y	WO, A, 92/10591 (CAPON ET AL.) 25 JUNE 1992, see entire document.	1-19
Y	SCIENCE, Volume 260, issued 28 May 1993, M.I. Johnston et al., "Present status and future prospects for HIV therapies", pages 1286-1293, see entire document.	1-19



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:	*T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z*	document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means		
P document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

01 MAY 1995

Date of mailing of the international search report

08 MAY 1995

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

BRIAN R. STANTON

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US95/00454

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	CELL, Volume 52, issued 11 March 1988, Q.J. Sattentau et al., "The CD4 antigen: Physiological ligand and HIV receptor", pages 631-633, see entire document.	1-19
Y	DNA AND CELL BIOLOGY, Volume 9, Number 5, issued 1990, G. Zettlmeissl et al., "Expression and characterization of human CD4: Immunoglobulin fusion proteins", pages 347-353, see entire document.	1-19
X	WO, A, 92/15322 (SEED ET AL.) 17 SEPTEMBER 1992, see entire document.	1-19
Y	Nature, Volume 337, issued 09 February 1989, Capon et al., "Designing CD4 Immunoadhesins for AIDS Therapy", pages 525-531, see entire document.	1-19

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US95/00454

B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

Databases: APS, CA, CAPREVIEWS, BIOSIS, MEDLINE, GENBANK, EMBASE

Search Terms: cd?; igg; immunoglobulin#; ch2; ch3; ctl; cytotoxic; lymphocyt?; nk; natural; killer; neutrophil?; granulocyt?; macrophag?; mast; hela; embryo?; stem?; es; alpha; heli?; tcr; t (w) cell; recept?; chimera?; chimera?; signal?; transduc?; fc; seed?/au; romeo?/au; kolanus?/au; banapour?/au; hiv; human; immunodeficien?; aids; htlv?; lav?; immunother?

THIS PAGE BLANK (USPTO)